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ABSTRACT 
In South Africa’s current healthcare structure, about 8.3% of GDP is spent on healthcare. This is 
well above the WHO recommended 5% of GDP spend. Despite the heavy spending, health 
outcomes remain poor when compared to similar middle-income countries. Solutions need to be 
found to cut back on healthcare costs. Approximately half (4.1%) of the healthcare spend is 
consumed by the private sector which benefits a very small segment (16%) of the population. 
This segment is largely on medical schemes. Using generic medicines can aid in cutting back 
on drug costs but are generics being adequately assimilated by the consumers of healthcare in 
the private sector? 
The objective of the study was to evaluate the perceptions attitudes and knowledge of the 
consumers of healthcare in the Northern suburbs of Johannesburg towards generic medicines. 
A survey was conducted on a sample of 402 respondents across 9 randomly selected 
pharmacies in the Johannesburg north region between November 2012 and February 2013. A 
researcher administered questionnaire was the sole data collection tool. Questions asked 
covered the research objectives and also included demographic data and other explanatory 
variables. Data analysis was carried out in SAS. The 5% significance level was used 
throughout, unless specified otherwise. The chi-squared (Χ2 ) test was used to assess the 
relationships between categorical variables. Fisher’s exact test was used for 2 x 2 tables or 
where the requirements for the Χ2 test could not be met. The strength of the associations was 
measured by Cramer’s V and the phi coefficient respectively. 
Key results on respondent demographics included high representation of the higher income 
earning groups (78% >R10 000); furthermore 44% had completed tertiary education, 60% were 
comprehensively insured, 61% regularly visited a pharmacy, 38% were on prescription 
medication and 24% on chronic medicine. On knowledge, 5% of respondents were able to most 
accurately define generic medicines. On attitudes, 78% had used generics however the level of 
agreement was lower for the highest education category (p<0.0001; Cramer’s V=0.18). Trends 
favoured brands over generics with increasing severity of illness as generics were chosen by 
10% in major illness and 5% in chronic illness. 80% perceived generics as safe while 95% 
perceived brands as safe. 75% of respondents felt that generic medicines were as effective as 
branded medicines. 15% indicated that branded medicines have fewer side effects. 64% 
showed positive perceptions of quality of generics compared to 93% for brands. Bowker’s test of 
symmetry was significant (p<0.0001) showing a shift towards slightly more negative perceptions 
towards generic medicines amongst those who thought highly of brand quality. 
Knowledge of generics was overall low. Perceptions regarding safety, quality, efficacy, and side 
effects of generic medicines were generally positive but responses proved more positive for 
brands. Attitudes towards generic medicines were mostly positive however willingness to use 
generics lessened with increasing severity of illness. Household income, health insurance 
(medical aid) status, level of education, experience with medicines and racial demographics 
played a key role in explaining consumer beliefs and behaviours. Pharmacists and Doctors had 
a positive influence on generic use patterns amongst other factors. 
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CHAPTER 1 – INTRODUCTION AND LITERATURE REVIEW 
1.0 Preface 
The state of the healthcare system in South Africa today is characterized by high healthcare 
expenditures, as well as inefficiencies in the use of medicines such that the questions need to 
be asked; Does it really matter if a drug is branded or generic, as one would assume that 
generics, being cheaper, should take the cake as every consumer’s first choice?  
Furthermore it also needs to be questioned; what is the impact of a person’s views on drugs 
either on their drug use habits or ultimately on the very state of public health or the economy of 
the country? This study sought to gain insight on these important questions and particularly 
within the demographic group of people who are currently the major consumers of healthcare in 
the country and could very well be responsible for driving the nations spiralling healthcare 
budgets.  
It is only fitting that in order to gain the best possible understanding; a firm foundation needs to 
be laid by covering a number of topics that surround the core issue before delving into the crux 
of the matter. The following introduction and review of literature seeks to tell the winding tale of 
generic medicines; from firstly establishing what they are, where they came from; their impact 
and place in the healthcare system, pharmaceutical markets, public health, policy and country 
economics; their benefits; and lastly the issues surrounding their use by the consumers of 
healthcare. 
1.1 Background 
1.1.1 What is a generic medicine?  
Generic medicines, also known as an interchangeable multi-source medicines, are defined as 
medicines that contain the same active substances which are identical in strength or 
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concentration, dosage form and route of administration and meet the same or comparable 
standards, which comply with the requirements for therapeutic equivalence as prescribed 
(Medicines and Related Substances Control Act 101 of 1965 as amended section 1 – 
Definitions, South Africa Government, 1997). 
A generic medicine is considered to be bioequivalent to the brand name drug if the rate and 
extent of absorption do not show a significant difference from the innovator drug or the extent of 
absorption does not show a significant difference and any difference in rate is intentional or not 
medically significant (Centre for Drug Evaluation and Research, 2008). According to the 
Medicines Control Council of South Africa:  
Two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent 
or pharmaceutical alternatives and if their bioavailabilities in terms of peak (Cmax and Tmax) and 
total exposure (AUC) after administration of the same molar dose under the same conditions 
are similar to such a degree that their effects with respect to both efficacy and safety can be 
expected to be essentially the same. Bioequivalence focuses on the equivalence of release of 
the active pharmaceutical ingredient from the pharmaceutical product and its subsequent 
absorption into the systemic circulation. Comparative studies using clinical or pharmacodynamic 
end points may also be used to demonstrate bioequivalence (Medicines Control Council, 2011).  
The statistical method for testing average bioequivalence is based upon the 90 % confidence 
interval (significance level) for the ratio of the population means (Test/Reference) for the 
parameters under consideration for example for the AUC, Cmax, and Tmax values. More 
specifically, the pharmacokinetic parameters derived from measures of concentration, e.g. AUC 
and Cmax are analysed using ANOVA (analysis of variance).  Data for these parameters are 
transformed prior to analysis using a logarithmic transformation (Medicines Control Council, 
2011). 
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If appropriate to the evaluation, the analysis technique for Tmax should be non-parametric and 
should be applied to untransformed data. In addition to the appropriate 90 % confidence 
intervals, summary statistics such as geometric and arithmetic means, SD (standard deviation) 
and % RSD (percentage relative standard deviation), as well as ranges for pharmacokinetic 
parameters (minimum and maximum), should be provided (Medicines Control Council, 2011). 
For example for total AUC ratio the 90 % confidence interval for the test/reference ratio should 
lie within the acceptance interval of 0,80 - 1,25 (80 – 125 %) and for Cmax ratio the 90 % 
confidence interval for the test/reference ratio should lie within an acceptance interval of 75 – 
133 %, calculated using log-transformed data, except for narrow therapeutic range active 
pharmaceutical ingredients when an acceptance interval of 80 – 125 % will apply (Medicines 
Control Council, 2011). 
Generic medicines typically enter the pharmaceutical market after the expiry of patents provided 
that bioequivalence to the original molecule is confirmed (Quintal & Mendes, 2011). They are 
also typically sold at a substantially lower price, as their development process is relatively brief 
and less costly (Teva Pharmaceutical industries, 2013). 
Generics medicines can be marketed as branded products – that is, with a trade name 
belonging to the producer of the generic or under the generic name of the active compound also 
known as the International Non-Proprietary Name (INN). There are obstacles to the market 
entry of generics but in most instances these obstacles are not technical, but derive from 
institutional arrangements, including the prescribing behaviour of doctors, brand loyalties, and 
regulatory and reimbursement systems, including retail or institutional pharmacy regulation and 
practices (Lofgren, 2004). 
The Medicines and Related Substance Control Act 101 of 1965 of South Africa as amended in 
1997, section 22F (South Africa Government 1997; implemented 02 May 2003) has a provision 
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that in summary compels pharmacists to offer patients a generic substitute for any medicine 
prescribed. The act categorically states that a pharmacist shall inform all members of the public 
who visit his or her pharmacy with a prescription for dispensing, of the benefits of the 
substitution for a branded medicine of an interchangeable multi-source medicine; and dispense 
an interchangeable multi-source medicine instead of the medicine prescribed by a medical 
practitioner, dentist, practitioner, nurse or other person registered under the Health Professions 
Act, 1974, unless expressly forbidden by the patient to do so.  
The Medicines and Related Substance Control Act 101 of 1965 of South Africa as amended in 
1997; section 22F also states other conditions under which a pharmacist may not dispense a 
generic medicine which are - that a pharmacist may not dispense a generic medicine if the 
person prescribing the medicine has written in his or her own hand on the prescription the words 
'no substitution' next to the item prescribed; if the retail price of the generic medicine is higher 
than that of the prescribed medicine; or where the product has been declared not substitutable 
by the Medicines Control Council (Medicines and Related Substances Control Act 101 of 1965 
as amended, section 22F). 
1.1.2 History of generic medicines 
Where exactly did generics come from? The history of generic medicines dates back to the 
1920s, when the company that made Bayer aspirin fought vigorously to keep generic versions 
off the shelves. The company lost in court, and consumers suddenly had an array of choices in 
generic aspirin. At the time, there wasn’t any regulation on how the generic versions were 
manufactured (Centrahealth, 2012). 
Later on in the 1950’s patent laws came into place in the United States designed to encourage 
innovation in the pharmaceutical industry. These laws stifled the generic medicines market as 
generic manufacturers had to wait until the patent had expired to start manufacturing generic 
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version of the innovator drug (Generic Pharmaceutical Association, 2012). Patent protection 
laws made it possible for innovators to protect their intellectual property for a period of 17 years 
from the date of the patent was issued or 20 years from the date submitted to the patent office. 
This translated to approximately 12 years of marketing protection considering the timeline for 
development of the drug (Centre for Drug Evaluation and Research, 2008). 
It wasn’t until 1984 that a decisive moment came in the development of the generics industry. 
The United States Drug Price Competition and Patent Restoration (Hatch-Waxman) Act was 
established which essentially provided for facilitated market entry for generic versions of all 
post-1962 approved products, in exchange for an extension of the patent period (Congressional 
Budget Office, 1998). The Hatch-Waxman Act created an abbreviated mechanism for approval 
of generic copies of all drugs originally approved after 1962, by stating that pre-clinical and 
clinical testing that is required for innovator drugs does not have to be repeated for generics 
(Centre for Drug Evaluation and Research, 2008). This opened the floodgates for generic 
competition of pharmaceutical products, creating the modern generic pharmaceutical industry 
(Lofgren, 2004) 
However, it wasn’t until the 1990s that generic competition altered the dynamics of the US 
pharmaceutical market significantly. A key driver was the spearheading by Health Maintenance 
Organizations and Pharmaceutical Benefit Management companies of cost-containment 
measures such as generic prescribing, brand substitution by pharmacists, and reimbursement 
on the basis of cheapest brand (Lofgren, 2004). By 1997, 63% of Health Maintenance 
Organizations are said to have imposed mandatory generic substitution (Mrazek & Mossialos, 
2000). When a generic now enters the US market, ‘the bottom almost immediately falls out of a 
branded product’s volume’ (Lipson, 2001). It is reported, for example, that Eli Lilly lost 80 
percent of its US market share for its anti-depressant drug Prozac in the first week following the 
beginning of generic competition in 2001 (Lofgren, 2004). But brand products normally retain 
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substantial sales, sometimes even at prices exceeding those before the commencement of 
price competition. 
In South Africa, it can be said that the generic pharmaceutical industry became a more unified 
force in the late seventies. The National Association of Pharmaceutical Manufacturers (NAPM) 
was established in 1977, as a voluntary, non-profit organization consisting of South African, 
generics-based pharmaceutical manufacturers and distributors. Its primary objective was and 
remains the championing of affordable healthcare by promoting the use of generic medicines. 
Today the NAPM represents almost 90% of generic companies in South Africa and represents a 
generics market share of approximately 45%. The NAPM represents the majority of wholly 
owned South African pharmaceutical manufacturers, some international companies with part 
South African ownership as well as internationally owned generics manufacturers (National 
Association of Pharmaceutical Manufacturers, 2013). 
Innovator drug companies operating in South Africa have by and large felt the pinch of the entry 
of generic manufacturer competition. Certain innovator companies have claimed that mandatory 
generic substitution is unfair discrimination and others have even said that the quality of 
generics was much lower than their branded products. A case in point was the statement made 
by Mr G. Farber in 2001. The then CEO of SmithKline Beecham, told the South African 
Parliament that generic substitution “will remove the ability of my company to retain the profits 
from its pharmaceutical operations to which it is entitled as the result of substitution by default” 
(Treatment Action Campaign, 2001). 
Legislation that had been written and passed to govern generic medicine use in South Africa 
only became effective in early 2003 (Shevel, 2003). The Medicines and Related Substances 
Control Act amendment Act 90 of 1997 made section 22F of the Act official. This part as 
described above made it a requirement for Pharmacists to offer consumers a generic substitute. 
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The National Council of Provinces had passed the Medicines Act on 20 November 1997 and 
President Mandela signed the law on 25 November 1997 (Shevel, 2003). This law amended the 
Medicines and Related Substances Control Act, No. 101 of 1965.  The new law contained 
measures that would make medicines more affordable and improve the functioning of the 
Medicines Control Council (Shevel, 2003). This piece of legislation became a key driver of the 
use of generics as their promotion in the healthcare system had become almost mandatory. 
With the momentum of policies, legislation and increasing awareness amongst healthcare 
providers and consumers, generic suppliers emerged as giants in their own right in separation 
from the research-based industry – the so-called Big Pharma sector – but there is today 
interdependence and overlap between the innovator and generics sectors. Brand name firms 
often supply drugs also under generic labels, drawing on technical and production factors to 
establish first mover advantages. Conversely, some generic companies produce patented drugs 
under license from, or on contract for, brand name companies, and engage in patenting of 
dosage forms, release mechanisms etc. based on their own Research and Development (R&D) 
capacities (Lofgren, 2004). At times, identical drugs from the same production line appear in the 
same market at different prices as branded products and generics. For example, Acimax a drug 
used for ulcers and Gatroesophaegial reflux diseases and sold by Alphapharm in Australia is 
made by AstraZeneca, and is in every respect identical to Losec (Lofgren, 2004). Generics firms 
typically have production costs similar to those of Big Pharma, and the key difference is that 
generic firms expend less on marketing and R&D (Burstall, Reuben, and Reuben, 1999). 
Patent laws became a trend globally in 1994 under the TRIPS (Trade Related Aspects of 
Intellectual Property Rights) agreement of the World Trade Organization (WTO), which dictated 
that member countries must allow pharmaceutical products to be patented. In 2001, the WTO 
adopted the Doha Declaration, which indicates that the TRIPS agreement should be read with 
the goals of public health in mind, and allows some methods for circumventing pharmaceutical 
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monopolies: via compulsory licensing or parallel imports, even before patent expiration (WTO, 
2001). The Doha Declaration gave life to the generic medicines market in developing countries 
such as South Africa, Brazil and India. South Africa witnessed the dramatic rise of the country’s 
top two pharma companies Aspen Pharmacare and Adcock Ingram who are today generic 
giants.  
A case in point in the history of generic medicines in South Africa is that in March 2001, 40 
multi-national pharmaceutical companies brought litigation against South Africa for its Medicines 
Act, which allowed the generic production of antiretroviral drugs (ARVs) for treating HIV, despite 
the fact that these drugs were on-patent. (Pharmaceutical Manufacturers Association versus 
The President of South Africa, 2002). HIV was and is an epidemic in South Africa, and ARVs 
were at the time unaffordable for most South African citizens, and so the South African 
government committed to providing ARVs at prices closer to what people could afford. To do so, 
they would need to ignore the patents on drugs and produce generics within the country (using 
a compulsory license), or import them from abroad. The Indian pharmaceutical company Cipla 
audaciously offered to make the drugs at roughly 1/40th of the lowest price available from a 
patent holder, which stunned the world community. After massive international protest in favour 
of public health rights (including the collection of 250,000 signatures by the Médecins Sans 
Frontières (MSF)/ Doctors without borders), the governments of several developed countries 
(including The Netherlands, Germany, France, and later the US) backed the South African 
government, and the case was dropped in April of that year (Helfer & Graeme, 2011). 
According to the IMS Health 2011 annual report, more than 50% of South Africans now opt to 
use generic medicines rather than a brand name prescription drug. This showed a significant 
rise in generic penetration in the country from 10 years earlier, when generics took just more 
than 30% of sales (Independent Online, 2012). 
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Today, generic drugs are both widely available and carefully regulated (Centrahealth, 2012). As 
can be seen from this brief summary of their history, generics are not a new thing. They have 
been around and have evolved over quite some time. 
1.1.3 The Drug Market 
How does the drug market work and where do generics stand in it?  
1.1.3.1 South Africa’s Macro Economics 
The outlook on the South African economy is neither one of doom nor boom. While South 
Africa’s GDP (gross domestic product) has grown despite the global financial crisis, it is not at 
the levels of the emerging markets of BRIC countries (Brazil, Russia, India and China) of which 
it is a member. South Africa has a restricted and possibly declining home market, a low value-
added export structure, a historically low savings and investment rate, an inadequate education 
system, a strong but volatile rand and serious infrastructure bottlenecks (IMS Health, 2012). 
1.1.3.2 Overview of the Global Pharma Market 
There has been rapid growth in the global generic pharmaceutical industry which has been 
propelled by several factors, including governments’ and healthcare funders need to control the 
rapidly increasing healthcare expenditures, a growing middle class in emerging markets, and a 
longer life expectancy (Harding, 2010). A large number of innovator drug patents have expired 
over the years, many of them ‘blockbusters’, and this has also contributed to the growth of the 
generic drug industry (Harding, 2010). A blockbuster drug is defined as an extremely popular 
drug that generates annual sales of at least 1 billion dollars for the company that creates it 
(European Commission, 2008). Blockbuster drugs worth 150 billion dollars are set to lose patent 
protection between 2010 and 2017 alone (Chidambaram, 2012). The global prescription generic 
industry, worth less than $50 billion in 2004, stood at over $80 billion by 2010 (Harding, 2010). 
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In the United States alone, generic sales have more than tripled since 2000 and exceed $51 
billion (IMS Health, 2009). IMS Health, a US-based organisation that analyses healthcare 
dynamics, forecasts that medicine spending in the developing world will double over the next 
five years. Of those sales, 83% were predicted to be generics, over-the-counter medicine and 
diagnostic and non-therapeutic products (Mail and Guardian, 2012).  
According to IMS data, by 2016 pharmaceutical spending in Africa is expected to reach $30bn, 
driven by a 10.6% annual growth rate that is second only to Asia and in line with Latin America. 
By 2020 the market will have more than doubled to $45bn. Although it is likely to remain a niche 
market, the promise of Africa is that it will continue to grow in the next decade as Asia and Latin 
America start to reach maturity (Barton, 2013). By contrast, as recently as 2010, the 
pharmaceutical industry in such established markets as the United States, Europe, and Japan 
was expected to only grow at single-digit rates. Therefore, it is not surprising that multinational 
generic companies and most major innovators alike are interested in expanding in emerging 
markets (Harding, 2010). 
Internationally the generics industry is dominated by multinational firms such as Teva (Israel), 
Sandoz (Germany), Mylan (US), Watson (US), Hospira (US), Sanofi (France), Actavis (Ireland), 
Daiichi (Japan), Aspen (South Africa), and Stada (Germany) who make up the global top ten 
generic companies by revenue in that order (World Pharmaceutical Frontiers, 2011). In 2011, 
their combined revenue was approximately 41 billion dollars and they showed a combined 
average growth of 13% over 2010 (World Pharmaceutical Frontiers, 2011). The overall global 
generic pharmaceuticals market was valued at approximately 124 billion dollars in 2010, 
growing at 11%. The United States alone is the world’s largest generics market constituting 45% 
of the market share. Emerging markets, particularly Brazil, Russia, India, and South Korea 
present growth opportunities of 15% to 20% (Chidambaram, 2012).  
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1.1.3.3 Overview of the South African Pharma Market 
South Africa (SA) was one of the world's fastest growing pharmaceutical markets, generating 
nearly ZAR28.9 billion (USD 2.7bn) in pharmaceutical sales in 2011. Although pharmaceutical 
sales in SA only account for less than 1% of the global pharmaceutical market, it is growing 
rapidly and has moved into the top 30 global markets since 2011. The total pharmaceutical 
market is expected to grow at a CAGR (compound annual growth rate) of 7.8% (±2.0%) over 
the period 2011-2016, reaching ZAR38.9 billion by 2016. This strong growth is due to changing 
demographics, rising incomes, modernisation of health systems and an increase in the 
treatment of chronic diseases, which creates a greater demand for medicines. Within the 
pharma market, unbranded generics are the smallest, yet the fastest growing segment (IMS 
Health, 2012). 
The pharma industry has grown 11% CAGR in the last 5 years, noticeably faster than GDP 
growth. Retail pharmacy sales contribute the most to this growth. Generic penetration in South 
Africa is higher than all benchmark countries except for New Zealand. The benchmark countries 
are Australia, Canada, New Zealand, and Spain. The generics market accounted for 32.8% of 
the market by value and 55.6% by volume in the year ending 31 March 2011 (IMS Health, 
2012). 
In South Africa the top 2 performing pharma companies overall are the generic giants Aspen 
Pharmacare and Adcock Ingram. Aspen alone holds a double digit market share of 17.5 percent 
outshining the competition that follow in single digit figures as seen in Table 1. All of the top 6 
performing pharma countries in South Africa are participating in the generics market (pure 
generic or innovator with generic division and together the top six pharma companies hold 
approximately 52.7% of the market share) (NAPM, 2012). 
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Table 1: Top pharma companies in South Africa 2011, (NAPM, 2012) 
CORPORATION ZARmio 
MAT/9/2011 
                                   
 
 
USDmio 
MAT/9/2011 
CAGR 07-
11 
MAT/9/2011 SHARE 
ASPEN 5,128.7 736.2 15.4% 2.4% 17.5% 
ADCOCK INGRAM 2,679.9 384.7 9.9% -8.8% 9.2% 
SANOFI 2,387.3 342.7 15.6% 12.0% 8.2% 
PFIZER 2,092.6 300.4 12.9% 13.5% 7.2% 
NOVARTIS 1,671.1 239.9 8.6% 8.6% 5.7% 
CIPLA MEDPRO 1,427.0 204.8 22.7% 14.6% 4.9% 
ASTRAZENECA 1,243.6 178.5 16.8% 3.7% 4.3% 
MERCK & CO 1,047.3 150.3 0.1% 6.5% 3.6% 
ROCHE 1,044.9 150.0 10.7% 7.2% 3.6% 
JOHNSON & JOHNSON 1,029.4 147.7 8.5% 5.9% 3.5% 
BAYER 925.1 132.8 9.4% 2.8% 3.2% 
ABBOTT 819.0 117.6 13.0% 9.1% 2.8% 
LILLY 532.5 76.4 12.0% 11.0% 1.8% 
NOVO NORDISK 449.8 64.6 5.0% -1.6% 1.5% 
BOEHRINGER INGEL. 410.1 58.9 8.6% 5.2% 1.4% 
DAIICHI SANKYO 393.7 56.5 7.3% 5.4% 1.3% 
MERCK KGAA 373.1 53.5 12.1% 4.9% 1.3% 
SERVIER 354.8 50.9 4.4% -7.9% 1.2% 
LUPIN LABORATORIES 298.0 42.8 31.0% 33.4% 1.0% 
GRAND TOTAL 29,258.0 4,199.6 6.6% 10.5% 100.0% 
ZARmio – Millions of rand; USDmio – Millions of US dollars; MAT/9/2011 – Moving Annual Total 
September 2011; CAGR 07 – Compound Annual Growth Rate July 2011; SHARE – Market 
share 
Strictly looking at the generic industry in South Africa, the top generic companies in this sector 
are as listed in Table 2. The top 3 generic companies hold approximately 50.7% of the market 
share. The top 6 generic corporations are also investing in local manufacturing of their products 
(NAPM, 2012). 
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Table 2: Top generic companies in South Africa, 2011 (NAPM 2012) 
CORPORATION ZARmio 
MAT/9/2011 
                                   
 
 
USDmio 
MAT/9/2011 
CAGR 07-
11 
MAT/9/2011 SHARE 
ASPEN 2,300.8 330.3 12.7% 1.3% 25.1% 
ADCOCK INGRAM 1,179.2 169.3 7.7% 10.5% 12.9% 
CIPLA MEDPRO 1,167.6 167.6 21.1% 10.1% 12.7% 
SANDOZ 810.0 116.3 8.9% 11.7% 8.8% 
RANBAXY 360.3 51.7 9.2% 4.1% 3.9% 
WINTHROP 322.5 46.3 63.8% 44.2% 3.5% 
PHARMA DYNAMICS 283.8 40.7 32.9% 35.9% 3.1% 
PHARMAPLAN 169.7 24.4 37.4% 30.2% 1.9% 
MYLAN 140.4 20.1 31.6% 41.2% 1.5% 
INOVA PHARMA 124.3 17.8 31.4% 29.6% 1.4% 
BRISTOL-MYERS SQB. 119.4 17.1 19.7% 16.1% 1.3% 
WATSON 114.1 16.4 24.3% 7.0% 1.2% 
FRESENIUS 111.9 16.1 13.0% -9.2% 1.2% 
MERCK & CO 117.7 16.0 4.6% -3.1% 1.2% 
AUSTELL CORP. 103.6 14.9 54.5% 17.4% 1.1% 
DR REDDYS LAB 98.3 14.1 50.8% 40.5% 1.1% 
THEBE MEDICARE 92.2 13.2 22.4% 10.0% 1.0% 
BE-TABS 87.9 12.6 332.5% -2.4% 1.0% 
JOHNSON & JOHNSON 86.4 12.4 12.0% 11.1% 0.9% 
GRAND TOTAL 9,172.9 1,316.6 16.4% 10.5% 100.0% 
ZARmio – Millions of rand; USDmio – Millions of US dollars; MAT/9/2011 – Moving Annual Total 
September 2011; CAGR 07 – Compound Annual Growth Rate July 2011; SHARE – Market 
share 
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1.1.3.4 Global market shares 
Globally, the highest market share for generics is found in industrialized countries where the 
industry historically had the greatest pricing freedom (King & Kanavos, 2002). The top eight 
global generic markets are the US, Germany, France, Canada, Italy, Spain and Japan and they 
account for 80% of the total generic sales. In terms of disease area, Cardiovascular and Central 
Nervous System generics are the two largest market segments, constituting nearly 38% of the 
global generic pharmaceutical market together. Respiratory and Oncology generics are likely to 
show significantly high growth rates whilst the Diabetes and Genitourinary/hormonal segments 
are expected to decline by 2017 (Chidambaram, 2012).  
As innovators have witnessed the growth in the generic industry and struggle to cope with 
pending patent expiries, many of them have turned to acquisitions and supply agreements to 
expand into generic drug markets as well. 
Novartis is one of the few innovator-focused pharmaceutical companies that stayed active in the 
generic drug industry even while other pharma companies divested their generic arms in the 
1990s. Novartis not only used mergers and acquisitions as a means to become involved with 
generics, but also as a means to gain entry into new generic markets (Harding, 2010). After re-
branding their numerous generics businesses as Sandoz in 2003, Novartis (Sandoz) went on to 
become one of the largest generic pharmaceutical companies worldwide, mainly through 
acquisitions (Sandoz, 2013). 
Pfizer provides another example. After divesting numerous generic-focused facilities to 
companies such as Teva (Israel), Torrent (India), and Actavis (Ireland), the world’s leading 
pharma company ventured back into generics, having created a business unit in 2008 
appropriately named “Established Products,” for the purpose of marketing generic drugs. Pfizer 
signed an agreement with Aurobindo Pharmaceuticals (India) in March 2009 for multiple generic 
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oral solid and injectable drugs and extended the agreement in June 2009. In January 2010, 
Pfizer entered into a collaboration agreement with Strides Arcolab of India, for the supply of 40 
off-patent products, including mostly injectable anti-cancer treatments. In the same year, it also 
acquired a large stake in Laboratorio Teuto, a large generics company in Brazil (Harding, 2010). 
Both Gilead Life Sciences and GlaxoSmithKline have signed agreements with South Africa’s 
Aspen Pharmacare for distribution of drugs in the region. In April of 2005, Gilead and Aspen 
Pharmacare signed a letter of intent under which they committed to enter into a non-exclusive 
licensing and distribution agreement for Gilead's antiretroviral (ARV) products Truvada 
(emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate).  
Under the terms of the agreement, Aspen manufactures finished product for the 95 resource-
limited countries included in Gilead's Global Access Program and distributes the products in 
every country in Africa. Truvada and Viread are manufactured by Aspen according to U.S. 
standards for Good Manufacturing Practices (GMP), and distribute the products under their 
global trade names in specified countries (Gilead Sciences Inc., 2005).  
Gilead provides the active pharmaceutical ingredient (API) for its products to Aspen and 
transfers the necessary technology for tableting of the products in Aspen's U.S. Food and Drug 
Administration (FDA) approved facilities in South Africa. In addition, Aspen pursues regulatory 
approval for the products in the countries in Africa where one or both products are not already 
registered (Gilead press release, 2005).  
In May 2009 GlaxoSmithKline (GSK) acquired a 16-percent stake in Aspen Pharmacare as part 
of a deal that saw the two firms combining their commercial activities in sub-Saharan Africa, and 
several assets being divested to Aspen. GSK manufacturing facilities in Bad Oldesloe Germany, 
as well as eight specialist medicines were part of the deal. The products divested had combined 
sales of £56-million (about R712.5-million) in 2008 (GSK, 2009).   
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As can be seen, generics have a significant stake in the global drug market and in the South 
African market. Generic manufacturers are very competitive and are performing well. Some are 
at par or even outperforming originator companies. 
1.2 Policies and their impact on generics 
Where do generics fit into the countries policy framework? Are they a priority? 
1.2.1 South African National Drug Policy 
The South African National Drug policy was established, amongst other things, to offer a clear 
description of the approach by which pharmaceutical services in the country was managed. The 
policy supports the use of generic medicines. According to the National Drug Policy (NDP), the 
use of generic medicines is a recommended step to reduce drug costs and expenditure. It also 
contributes to a sound system of procurement and distribution, drug information and rational use 
at every level of the healthcare system (Department of Health, 1996).  
Hence from a policy perspective, the availability of generic, essential drugs is encouraged 
through the implementation of incentives that favour generic drugs and their production in the 
country. The policy aims at achieving generic prescribing in both the public and private sectors. 
Until this aim is achieved, generic substitution was allowed, through the legislation stated above, 
in both the public and the private sector. The patients will have the right to make informed 
decisions concerning their own health, including a choice for generic drugs (Department of 
Health, 1996). 
Another aim of the NDP is to promote the availability of safe and effective drugs at the lowest 
possible cost. This aim is being achieved by monitoring and negotiating drug prices and by 
rationalising the drug pricing system in the public and private sectors, and by promoting the use 
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of generic drugs. A pricing committee exists within the Ministry of Health with clearly defined 
functions to monitor and regulate drug prices.  
Committee members include health economists, pharmacoeconomists, representatives from the 
Department of Finance, the Department of Trade and Industry, the Procurement Unit of the 
Department of Health, the Department of State Expenditure, and consumer representatives. 
Total transparency in the pricing structure of pharmaceutical manufacturers, wholesalers, 
providers of services, such as dispensers of drugs, as well as private clinics and hospitals is 
highly sought after (Department of Health, 1996). 
As can be seen from the above policy summary, generics are here to stay and even the 
government has made provisions to ensure that they do. 
1.2.2 National Health Insurance – overhaul of the South African health system 
South Africa is currently in the process of introducing an innovative system of healthcare 
financing aimed at promoting efficiency and equity with far reaching consequences on the 
health of citizens. The introduction of National Health Insurance (NHI) will ensure that everyone, 
regardless of their socio-economic status, has access to appropriate, efficient and quality health 
services. There were major changes in the service delivery structures, administrative and 
management systems (Department of Health, 2011). 
NHI intends to eliminate the current tiered system to improve access to quality healthcare 
services and provide financial risk protection against health-related catastrophic expenditures 
for the whole population. Everyone will have access to a defined comprehensive healthcare 
services package which was provided through accredited and contracted public and private 
providers. 
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One of the objectives of NHI is to procure services on behalf of the entire population and 
efficiently mobilize and control key financial resources (Department of Health, 2011). As a 
national programme instituted by the government, it can be inferred that when it comes to 
procurement of pharmaceutical services, NHI will align itself with the South African National 
Drug Policy which as stated earlier aims at achieving generic prescribing in both the public and 
private sectors. It is therefore imperative that all consumers of healthcare have a good 
understanding and acceptance of generic medicines.  
1.3 The South African Healthcare system 
How does the healthcare system work in South Africa? Where do pharmaceuticals fit into the 
system? Who influences consumer choices? Where can cost containment strategies be 
targeted? 
1.3.1 Overview of the healthcare system 
The South African healthcare system is both dynamic and multi-faceted. It cannot be compared 
to any other healthcare system in the world. A major part of the healthcare system deals with 
how funding occurs. Healthcare financing in South Africa is two-tiered with a public and a 
private sector. Expenditure on medicines in the public health sector is largely subsidized (Leon 
& Mabope 2005; Pick, 2008) and the main funder is the fiscus. Healthcare expenditure at the 
local level is subsidised by central government, which refunds anything from 33% to 100% of 
the costs to the local authorities, depending on the type of service provided for community 
health and whether or not the drugs provided are on the Essential Drugs Lists (EDL). 
Health services in the public health sector are typically inefficient and suffering from severe staff 
shortages and poorly equipped facilities. There are significant regional disparities and 
differences between urban and rural healthcare provision. For a drug product to achieve full 
access to the public healthcare sector, it is necessary to win national government tender. These 
19 
 
tenders are open to the public market and are largely price driven however additional criteria 
differ per product (IMS Health, 2012)  
In the private sector, a relatively large amount of the funding is allocated through medical 
schemes, various hospital care plans as well as out of pocket payments. This current funding 
system provides cover only to private patients who have purchased a benefit option with a 
scheme of their choice or as a result of their employment conditions or benefits. It only benefits 
those who are employed and are subsidised by their employers in both the State and the private 
sector. Each Medical Aid typically provides various plans with varying contributions and 
consequent levels of coverage (IMS Health, 2012).  
Hence those with medical scheme cover have a choice of providers operating in both the public 
and private sector which is not extended to the rest of the population. In contrast to the public 
sector, for a drug product to achieve full access to the private healthcare sector, it is necessary 
for it to appear on the reimbursement list of each registered Medical Aid Scheme (IMS Health, 
2012). 
In the public sector healthcare provision is primarily based on tertiary hospital facilities. By 
contrast, in the private sector healthcare is delivered by private general practitioners (GPs) and 
specialists, with about 211 private hospitals. The private sector is also increasingly 
characteristically dominated by corporate for-profit groups (IMS Health, 2012). 
Zooming in on overall resource allocation in South Africa’s healthcare system, it is apparent that 
a significantly larger part of the financial and human resources for health in South Africa is 
located in the private health sector serving a minority of the population. Statistically, Medical Aid 
schemes are the major purchasers of services in the private sector which covers 16.2% of the 
population (Council for Medical Schemes, 2009). This means that only about 16% of the 
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country’s population (7 million people) can afford high quality private healthcare (IMS Health, 
2012). 
1.3.2 Stakeholders 
The overview of stakeholders in the South African healthcare system is as presented in diagram 
1. 
  
21 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
Diagram 1: Stakeholders in the South African healthcare system (IMS Health, 2012) 
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KEY OF ACRONYMS: SANAC – South African National Aids Council; BHF – Board of 
Healthcare Funders; MCC – Medicines Control Council; SAHPRA – South African Health 
Product s Regulatory Authority; DoH – Department of Health; PMB – Prescribed Minimum 
Benefit; CDL – Chronic Disease List; GP – General Practitioner 
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The influence on drug choice has seen a shift over time amongst the various stakeholders in the 
healthcare system. In the past the prescribing doctor had been the key influence in the drug 
choice but this trend has been declining. On the other hand the influence of the healthcare 
funder/payer, pharmacists, and key opinion leaders on drug choice has seen an increase whilst 
the influence of patient groups has not changed over time. This is illustrated in diagram 2 (IMS 
Health, 2012). 
Influence and Power of stakeholders from 2008 - 2013 
    National payers   Local payers             Doctors       Pharmacists       Patient group        Key opinion                      
leaders 
 
 Decrease           Increase               Stay the same 
 
Diagram 2: Influence and power of stakeholders on drug choices 2008 - 2013 
Prescribing and reimbursement controls combined with generic substitution have served to 
diminish the influence of prescribing doctors (IMS Health, 2012). Compulsory generic 
substitution makes it difficult for original brands to compete. Patients are pushed towards lower 
priced medicines unless they are willing to pay a higher co-payment. Patients are fully funded 
up to a certain point. As long as they do not exceed the threshold, patients have a greater 
choice of the medicine they receive. Pharmacy Benefit Managers (PBMs) perform real-time 
electronic claims analysis at the point of dispensing so that they can approve reimbursement or 
not and indicate the required co-payment. PBMs communicate with doctors and patients to 
inform them of the availability of generics to encourage switching. Sometimes certain medicines 
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can only be prescribed by specialists and the patient will not be reimbursed if they get the 
prescription from any other practitioner (IMS Health, 2012). 
The top players in the medical scheme industry make up approximately 16% of the market 
share for all Medical Aids. They also account for 80% of members and 80% of total benefits. 
Discovery health on its own takes up the largest portion with 28% market share of members. 
The Government Employees Medical Scheme (GEMS) takes up 13% of medical scheme 
members (IMS Health, 2012). 
1.3.3 Distribution of Pharmaceutical products in the South African healthcare system 
Generally, distribution of pharmaceutical products follows a multi-layered and highly regulated 
system. Pharmaceutical companies supply their products to wholesalers who themselves sell to 
retail pharmacies, private hospitals or clinics, provincial centres or hospitals, as well as 
dispensing doctors (IMS Health, 2012). The end consumer will therefore only receive the 
product from the pharmacy, hospital/clinic, or dispensing doctor. The National Association of 
Pharmaceutical Wholesalers (NAPW) represents most of the wholesalers while the South 
African Pharmacy Council is responsible for the regulation of all wholesalers of registered 
medicines (Pharmacy Act 53 of 1974). Approximately 20 players dominate the entire wholesale 
market in South Africa (IMS Health, 2012).  
Retail pharmacies are a major outlet of pharmaceutical products to consumers. There are over 
2750 registered retail pharmacies in the country (South African Pharmacy Council, 2013). Most 
are privately owned and part of a chain. Many of the retail chains are strongly affiliated to a 
wholesaler. The retail pharmacy industry is also regulated by the South African Pharmacy 
council (Pharmacy act 53 of 1974). 
Both prescription and non-prescription products can be provided direct to consumers by 
hospitals, clinics, retail pharmacies, and dispensing doctors. Supermarkets and grocery stores 
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are only authorized to supply non-scheduled proprietary products like certain cough medicines, 
specific pack sizes of certain pain killers such as aspirin and paracetamol as well as an array of 
non-regulated complementary medicines (Medicines and Related Substances Control Act 101 
of 1965 as amended section 22A). It is possible however for a retail pharmacy to be established 
within a supermarket and be able to sell a more complete assortment of pharmaceutical 
products direct to consumers. 
1.3.4 Pricing  
The pricing of pharmaceuticals in South Africa is highly controlled by the government. Prices in 
the private sector are controlled by the single exit pricing (SEP) system. In this system the price 
at which a pharmacy purchases drugs from its suppliers is set and cannot vary between 
suppliers (Motsoaledi, 2010). The price is made up of the ex-factory price plus the logistics fee 
and 14% VAT. In addition under the SEP system, manufacturers must sell their medicines at the 
same price to all their customers, regardless of the volume purchased. The only exception 
comes at the retail pharmacy level where prices do not have to be uniform across pharmacies. 
In certain situations, for example due to exchange rate fluctuations and a high level of inflation, 
the government at times allows for manufacturer's to apply for price increases. The SEP system 
also includes provisions for an annual review of pricing, at the discretion of the Minister of 
Health (Motsoaledi, 2010). 
Over-the-counter (OTC) products classified in schedules 1 and 2 of the Medicines and Related 
Substances Control Act 101 of 1965, which can only be sold through pharmacies, are subjected 
to the same pricing structure as prescription drugs. For schedule 0 products, which are in the 
lowest schedule and are allowed to be sold outside pharmacies, the regulations state that the 
percentage mark-up that applied in 2004 when the SEP regulations were first introduced may 
not be exceeded (Motsoaledi, 2010). 
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Supplying the public sector follows the tender system and prices are about 20-40% lower than 
the Standard Exit Price (SEP) when companies are bidding for tenders. The system is open to 
all companies and is operated on a low-price, high-volume basis. It is therefore no surprise that 
tenders are dominated by generic companies. During tender selection, a point system is used 
which is largely price driven as is mentioned above. Other preferential considerations include 
whether the product is locally produced and whether or not the companies have reached black 
economic empowerment (BEE) targets. 
As a result of the preferential award of tenders to local producers, some multinational 
companies have strategically resorted to outsource production of products suitable for the 
tender market to local third parties so that they can compete even with the lowest cost Indian 
suppliers (IMS Health, 2012). The tendering system is currently set to undergo some changes 
however. The Department of Health (DoH) is in the process of taking control of medicine 
tenders from the Treasury and is also pressing ahead with setting up its own Central 
Procurement Unit (CPU). The idea behind this is to limit opportunities for corruption at provincial 
DoH level, increase efficiency and lower costs (Motsoaledi, 2010). 
The pharmaceutical pricing policy itself is determined by the Pricing Committee which is an 
advisory body made up of experts appointed by the minister of health (Medicines and Related 
Substances Control Act 101 of 1965 as amended section 22G). Pricing reviews are based on 
the SEP formula, which takes into account the following factors from each preceding year: 
average consumer price index (CPI); average producer price index (PPI); changes in foreign 
exchange rates and purchasing power parity; comments received from interested parties; and 
the need to ensure the availability, affordability and quality of medicines. The CPI changes are 
weighted 70% on the basis of historical CPI, 15% to changes in the rand against the US dollar 
and 15% to fluctuations in the rand/euro rate (Motsoaledi, 2010). 
26 
 
The prices of medicines in South Africa will be even more strictly regulated during the next five 
years in both the private and public sectors (Motsoaledi, 2010). There is a high level of control 
regarding price setting for new products on the market through the SEP set by the government. 
However, if all the correct documentation, as outlined by the Medicines Control Council, is 
submitted to the Pricing Committee, it can take place with few difficulties. 
Of note, the SEP was increased by 2.14% in 2012 and there have been several price increases 
since 2008. A maximum price increase of 7.4% occurred in April 2010 and prior to that a 13.2% 
increase occurred in February 2009. The 2009 increase reflected serious difficulties in the 
economy which occurred in 2008 caused by sharp rises in imported raw material costs as the 
rand value weakened. For 2011, it was decided by the government to freeze prices (IMS Health, 
2012). With plans to introduce NHI further important price changes are imminent, including long-
awaited International price benchmarking, price negotiation for new products and new supply 
chain fee regulations (Motsoaledi, 2010).  
In the private market, prices will remain strongly influenced by Medical Aid Scheme 
reimbursement policies. It is estimated that 98% of the schemes use reference pricing to lower 
prices, while public sector prices will remain lowered substantially by the tender system for 
public procurement (IMS Health, 2012). The standardisation of SEP prices has become 
particularly damaging because Medical Aid Schemes are increasingly demanding lower prices 
in exchange for formulary listing. This means that if a company wants to have its product listed 
on one formulary it must be prepared to reduce the SEP for all the others in the country as a 
whole. 
Prices in South Africa have not fallen as quickly as in other countries once a product goes off 
patent and with caps on generic prices now a feature of many other markets, the imposition of 
ceilings on the price of early generic entrants at some point in the next five years cannot be 
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ruled out entirely. The current main driver of generic price competition is reference pricing, 
which is applied widely by Medical Aid Schemes to limit their pharmaceutical reimbursement 
costs (Motsoaledi, 2010). Traditionally, medical schemes used molecular reference pricing 
mechanisms, but a number of schemes have begun to apply the measure reference pricing at 
therapeutic class level in recent years (IMS Health, 2012). 
As recently as 2008, less than 10% of medical scheme options applied therapy-level reference 
pricing mechanisms to determine pharmaceutical reimbursement rates, but data from the 
Mediscor Medicines Review showed that the figure had risen to 20% by 2010 (Badenhorst & 
Bester, 2011). 
In summary, pharmaceuticals play a key role in the country’s healthcare system. Healthcare 
funders, Prescribers, and Pharmacists play key roles in the healthcare sector and have vast 
influences on consumers of healthcare. Cost containment on pharmaceuticals is a key pressure 
point both from a public and private sector perspective. 
1.4 Healthcare expenditure in South Africa 
How does South Africa compare to global standards and norms? What is the impact of our 
healthcare spending? Who is responsible i.e. who is the protagonist in spending on healthcare? 
Over the years, expenditures for healthcare in the private sector have grown to consume a 
much larger proportion of the total national expenditure on health. In the 1970s, 30% of all 
healthcare expenditures were concentrated in the 20% of the population that had private 
insurance (Benatar, 2004). In 2005−2006, South Africa spent approximately 8.7% 
(approximately R135 billion) of its GDP on health sector financing (World Health Organization, 
2008). Of this amount, 56% went through the Medical Aid industry that serves the private 
healthcare sector (Blecher & Harrison, 2006; Department of Health, 2007). Healthcare spending 
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levels are comparable to middle income peers and are primarily financed by the private sector 
(IMS Health, 2012). 
According to the World Health Organization, a country should spend about 5% of its gross 
domestic product (GDP) on healthcare. At present, South Africa spends well above this amount 
with a figure of 8.3% of its GDP spent on health (National Treasure: Intergovernmental Fiscal 
Review, 2010). Health outcomes however remain poor when compared to similar middle-
income countries. As a comparator, it has been reported that high-income countries spent an 
average of 7.7% of their GDP on health, middle-income countries spent 5.8% and low income 
countries spent 4.7% (Schieber et al., 2006). Spending on healthcare is projected to rise at 
rates comfortably in excess of economic growth during the next five years. Increases will be 
driven by factors such as higher government spending in the sector and rapid hikes in the cost 
of private healthcare. Spending will increase further in the longer term as the NHI (National 
Health Insurance) scheme is rolled out (IMS Health, 2012). 
In South Africa’s current healthcare structure, of the 8.3% of GDP that South Africa spends on 
health, approximately half (4.1%) is spent in the private sector and 4.2% in the public sector. 
The 4.1% spent on the private sector covers 16.2% of the population (8.2 million people) who 
are largely on medical schemes. The remaining 4.2% is spent on 84% of the population (42 
million people) who will mainly utilize the public healthcare sector (National Treasure: 
Intergovernmental Fiscal Review, 2010). 
It is clear from the statistics stated above that the private healthcare sector which provides 
services to a minority of the South African population, is responsible for approximately half of 
the country’s annual healthcare expenditure. It can be assumed that the majority of those on 
private health insurance (medical aid) are the higher income earners in the population who can 
afford it. These higher income earners can be stratified according to the suburb they live in. 
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A recent survey showed that out of the top ten highest income suburbs of South Africa, seven 
were actually from Johannesburg. By region the top earning suburbs or metro towns are as 
follows: In Johannesburg the suburbs of Fourways (Sunninghill, Lonehill, and Dainfern), 
Bedfordview, Sandton and Midrand. Most of the suburbs just mentioned are located in the 
Northern Parts of Johannesburg; in Pretoria, the suburbs of Pretoria East and Centurion. 
In Durban, the suburbs of Durban North, Umhlanga, Highway area and Amanzimtoti; In Cape 
Town the suburbs of Somerset West, Durbanville, Milnerton (Cape Town north areas); and 
lastly in outlying areas which include the suburbs of Polokwane, Ballito, Witbank/ Middelburg, 
Rustenburg and Empangeni (Average urban household income, 2010). 
In summary, the private sector has become the protagonist in healthcare spending in South 
Africa and costs are spiralling out of proportion compared to the country’s economic 
performance. It is therefore important to study the beliefs and behaviour patterns of those that 
constitute the private sector specifically the end consumer. From an affordability stand point the 
group of higher income earners in the country are the key consumers in the private sector. It is 
important to determine their knowledge of generic medicines as well as their attitudes and 
perceptions towards generics and possibly find ways of positively influencing these factors. This 
group consumes a significant portion of the health services in the country which has a 
significant impact on the economy and with the introduction of National Health Insurance their 
consumption patterns will significantly impact national health policies and national healthcare 
budgets. The selection of Johannesburg North for this study is as a representative of the entire 
group of higher income earners in the country. 
1.5 Benefits of Generic drug use 
Increased use of generic medicines is an important means of controlling drug costs without 
compromising quality of care (Fischer & Avorn 2004; Kohl & Shrank, 2007). Generic medicines 
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are usually less expensive than the branded originator medicines and can potentially offer 
financial savings and release funds that can be better used elsewhere (Tsiantou, Zavras, 
Kousoulakou, Geitona, and Kyriopoulos, 2009).  
 
In developed countries such as Canada, Denmark, Netherlands, Germany, United States of 
America and the United Kingdom, policies have been implemented with a high rate of use of 
generic medicines resulting in large savings (Martin, 1999; European Generic Medicines 
Agency, 2010) 
 
Some research has been done in South Africa to show the influence of generic substitution on 
the cost of medicine. In 1990 Boyce and Bartlett shows that cost savings from generic 
prescribing and generic substitution can, depending on the item involved, range from 9.9% to 
59.7% (mean 41.1%) Later in 1996, Karim et al. reported that generic prescribing and 
substitution have the potential to reduce medicine costs by a further average of nearly 10% if 
practiced to maximum capacity in South Africa (Karim, Pillai, Ziqubu, Page, Cassimjee & Morar, 
1996). 
 
In addition to reducing total expenditures for prescription drugs, generic prescribing can have a 
substantial effect on adherence to treatment (Shrank et al., 2006).  
 
1.6 Facilitators and barriers to generic use 
Many factors may influence whether patients receive generic medications. Physicians write 
prescriptions and substantially influence the medication choice (Federman et al., 2007). Patients 
may request generic medications at the point of the clinical encounter or upon receipt of the 
medication at the pharmacy, and individual patient characteristics may influence generic drug 
use (Federman et al., 2006). Insurers use pharmacy benefit designs and tiered co-payment 
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requirements to steer patients towards less costly generic medications and this becomes a 
facilitator for use. Pharmacy characteristics may influence medication choice by influencing the 
rates that patients communicate about medication costs or by using protocols to increase 
generic medication use. 
In recent years, research has been undertaken to unravel both physician and patient facilitators 
and barriers associated with generic substitution. Patient willingness to accept a generic 
medicine has been identified as a core requirement of facilitating the uptake of generic 
medicines (Andersson, Sonesson, Petzold, Carlsten, and Lonnroth, 2005) 
 
1.7 Some consumer perspectives 
It is important to consider that when a patient gets a generic medicine they are receiving a 
product that not only has a different name from the original, but often has a different size, 
shape, colour and taste. A growing body of literature shows that people do not use medicines in 
a vacuum. Social cultural political and economic realities all contribute to how they are used 
(Van der Geest & Whyte, 1988; Foster, 1991; Whyte et al., 2002; Chetley et al., 2007). Studies 
have shown that some patients are sceptical about taking generic medicines for a variety of 
reasons such as confusion over the difference between the originator drug and the generic 
drug, or claims of noticing a poorer effect from the generic, or some patients noticing an 
increase in the side effects experienced when taking the generic drug (Bulsara et al., 2010). 
 
Generics are often considered inferior medicines (Minutes of the PHARMAC, 2007) and this 
could be due to various factors which include perceived poor compliance with good 
manufacturing practices (GMP), lack of patient’s knowledge about generic medicines and the 
influence of multinational drug companies (King and Kavanos, 2002). Though for economic 
reasons the trend is that the use of generic substitution is increasingly being supported by 
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health authorities (Meredith, 1996), but it is often met with some suspicion by both healthcare 
providers and patients (Meredith, 2003). It is important to note however, that often the patient 
loyalty to a brand can come into play and they may choose to pay the higher price for the brand 
name medication (Upfront: Brand Change, 2007). Other than brand loyalty, other factors need 
to be considered such as misunderstanding regarding ‘‘generic’’ as being “poor quality”. These 
factors could compel consumers to buy brand medicines. 
Lack of knowledge about generic drugs, negative attitudes towards them, or any negative 
perceptions about generic drugs could result in very low use of generics. This will have a 
negative impact on healthcare budgets. 
1.8 Similar studies – lessons learnt 
Several studies have been carried out around the world to evaluate consumers’ knowledge, 
perceptions and attitudes regarding generic medicine. A study in Auckland, New Zealand 
showed that consumer’s knowledge and understanding of generic medicine was overall low and 
generally consumers had a negative attitude regarding generic medicines. It was also felt that 
generics were an inferior version of the branded medicine and of not the same quality. The main 
sources of consumer’s knowledge were pharmacists, media and doctors (Babar et al., 2010).  
A study in Iraq on consumer perception on generic medicines showed a lack of awareness of 
generic medicines among Iraqi consumers. Not all participants in this study knew the term 
‘‘generic medicines.’’ This result is in line with a study conducted in Malaysia, where most of the 
Malaysian consumers did not know what generic medicines were (Thomas & Vitry, 2009), 
however it differs from other international studies for example in a German study, 63% of 
consumers had heard of the difference between generics and brand-name medicines, mainly 
from the media and/or their physicians (Himmel, Simmenroth-Nayda, Niebling et al., 2005).   
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A study carried out in the United States showed that among a sample of women enrolled in a 
U.S. government sponsored Medical Aid Scheme called TennCare, awareness of the benefits of 
generics (e.g., cost savings ability, equal effectiveness, and similar side effect profiles) did not 
equal preferences for personal use of generics. When it came to personal preference, results 
showed a much smaller proportion of women wanted to take generics over brand-name 
medications (Keenum et al., 2012). The same study also showed that patients who constituted 
the lower income group were strangely not receptive to taking generic medication themselves 
(Keenum et al., 2012).  
Participants in the Tenncare study also reported that healthcare providers both physicians and 
pharmacists infrequently discussed generic substitution with them (Keenum et al., 2012). These 
findings were important because communication with healthcare providers is a key element, 
along with the health professionals’ comfort with generic substitution, in positively influencing 
actual patient use of generics. As a result, it was a conclusion in this study that interventions 
should be designed to encourage two-way communication between healthcare providers and 
patients to promote use of generic medications (Keenum et al., 2012). 
In a review of the literature over the past 40 years, it is reported that there has there been an 
increase in the use of generics over the decades as well as a steady upward trend in patient 
knowledge and confidence toward the use of generics especially in developed countries 
(Hassali et al., 2009) 
Among a large cross-sectional sample of adults in the state of Wisconsin in the United States, 
Ganther and Kreling found that consumer perceptions of risk with generics compared to brand-
name medications differed as a function of the medical condition being treated (Ganther & 
Kreling, 2000). Another important study outcome is that both prescribers and pharmacists play a 
significant role in whether patients receive generic medication (Mott & Cline, 2002). Of 
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significance, using data from the 2003 National Ambulatory Medical Care Survey, Steinman et 
al. found that physicians were significantly more likely to refer to medications by their brand 
names, including those with generic equivalents (Steinman, Chren, & Landefeld, 2007). 
Sharrad and Hassali found that consumers’ main reason for using generic medicines was that 
they were less expensive. Physicians’ inclinations to prescribe brand-name medicines and lack 
of knowledge on generic medicines were the main barriers to accept the use of generic 
medicines. The study concluded that consumer education on generic medicines is important to 
correct misconceptions and give consumers the knowledge that they need to make an informed 
decision about using generic medicines (Sharrad & Hassali, 2011).  
The results of the Sharrad and Hassali study indicate that some people do not know the term 
‘‘generic medicines’’ as such but possibly are aware of or have had experience with a cheaper 
or commercial, equivalent alternative to a brand-name medicine. Most of the participants in the 
study knew that generic medicines were cheaper and of equivalent quality to brand name 
medicines. This result is in agreement with a study conducted in Brazil, where 70% of the 
consumers knew that generic medicines were both cheaper and equivalent to the brand-name 
medicines (Bertoldi, Barros, and Hallal, 2005).  
Consumers with experience of generic medicines generally had a more positive perception of 
them in the Iraq study (Sharrad & Hassali, 2011). Similar results were found in a survey on 
consumers’ perceptions of generic substitution conducted amongst a sample of 505 consumers 
in the United States (Sansgiry & Bhosle, 2004) and in a study conducted amongst a sample of 
804 patients in Germany (Himmel, Simmenroth-Nayda, Niebling et al., 2005).   
 Another finding in the Iraq study was that the cheaper cost of generic medicines was found to 
be one of the factors for choosing them (Sharrad & Hassali, 2011). Similarly, consumers 
interviewed in Australia by Hassali (Hassali, Kong, and Stewart, 2005) claimed that the main 
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reason for accepting generic medicines was their price. Physicians’ inclinations to prescribe 
brand-name medicines and lack of knowledge were found to be the main barriers on the use of 
generic medicines in the Iraq study (Sharrad & Hassali, 2011).  
In a nationwide study on generic medicines substitution practices of Australian community 
pharmacists and patient acceptance of this practice, it was revealed that the opportunity for 
Australian pharmacists to perform generic substitution was high as prescriber’s seldom 
restricted substitution (Chong, March, Clark, Gilbert, Hassali, and Bahari, 2011). The surveyed 
pharmacists demonstrated a very high generic substitution recommendation rate for eligible 
prescriptions (Chong, March, Clark et al., 2011). This scenario may have been influenced by the 
generic medicine substitution policy enacted by the government in Australia. Of interest, it was 
revealed that chronic patients had significantly lower levels of acceptance of generic substitution 
than the patients with acute conditions. Chronic patients who were stabilized on a brand product 
may have been sceptical about switching their therapy in case the alternative brand was not as 
effective (Chong, March, Clark et al., 2011). 
A study from Finland found similar findings where the majority of patients tended to refuse any 
substitution if they had positive experiences with medicines they had used previously (Heikkila, 
Mantyselka, Hartikainen-Herranen, and Ahonen, 2007). Another possibility is that chronic 
patients may have considered that cheaper generics were of inferior quality than the originator 
brand and subsequently refused substitution (Hassali, Kong, and Stewart, 2005). The lesson 
learnt here was that messages of reassurance about the quality, efficacy and safety of generic 
medicines should be a priority for pharmacists or relevant health professional or agencies to 
improve patient acceptance of generic medicines (Chong, March, Clark et al., 2011). 
The quality use of generic drugs cannot be improved without consumers’ informed involvement 
as it is believed that consumer’s perceptions may be a strong determinant of acceptance of 
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brand change (Minutes of the PHARMAC Consumer Advisory Committee, 2007). In New 
Zealand, though generics are commonly used, the public may simply associate generics with 
inferior products. The Pharmaceutical Management Agency (PHARMAC) is the New Zealand 
entity that decides on behalf of the district health boards, which medicines and related products 
are subsidised for use in the community and public hospitals. In a PHARMAC discussion, it was 
noted while the term ‘‘generic’’ is well understood by PHARMAC, the public may simply regard 
them as ‘‘cheap’’ (Minutes of the PHARMAC Consumer Advisory Committee, 2007).  
Some literature suggests that consumers believe that generics are sub-standard and have 
quality issues (King & Kanavos, 2002; Generic Medicines, 2007; Medsafe, 2012). A pilot survey 
in Malaysia found that there is a gap in consumers’ knowledge regarding generics and 
healthcare providers play a key role by providing education on generics (Al-Gedadi, Hassali, & 
Shafie, 2008). The efforts of consumers, pharmacists and prescribers are all essential in 
enabling better use of generic medicines (Babar & Awaisu, 2008). Consumers, in particular, are 
the decision makers, as making better use of generics would allow them to minimise the cost of 
their medicines, especially if they have chronic conditions (Babar & Awaisu, 2008). 
1.9 Aim 
The aim of the study is to evaluate the perceptions attitudes and knowledge of the consumers of 
healthcare in the Northern suburbs of Johannesburg towards generic medicines. 
1.10 Objectives 
 To gauge perceptions regarding the safety, quality and efficacy of generic medicines as 
well as compare these with brand medicines. 
 To assess consumers level of knowledge regarding generics. 
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 To ascertain willingness to use generic drugs and reasons behind decision. 
 To establish ways to influence generic use patterns in the higher income population of 
South Africa. 
 To describe the demographic variables measured as well as explain them in terms of 
their effect on the other variables measured. 
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CHAPTER 2 – METHODS 
2. Methods 
2.1 Data collection tool 
Data was collected through researcher administered questionnaires. A survey was conducted 
on consumer perceptions attitudes and knowledge on generic medicines in the Northern 
suburbs of Johannesburg using researcher administered questionnaires between November 
2012 and February 2013.  
2.2 Question selection 
 The questionnaire was developed by reading literature on and around the topic of generic 
versus branded medicine and on general discussions with consumers of healthcare. Electronic 
databases such as Science Direct and Pubmed were used to conduct a literature review 
regarding generic medicines issues across the world. This helped develop insights into the 
issues surrounding the use of generics and provided information about their safety, quality, and 
efficacy. A pilot study was conducted for the purpose of improving on the questionnaire. Some 
questions covered demographics and other potential explanatory variables, and the rest 
covered the aspects of knowledge, attitudes and perceptions and this gave the questionnaire a 
balanced composition. 
To determine knowledge about generics, participants were asked to define a generic medicine 
from a variety of answers provided as determined by literature (Hassali et al., 2009), (Keenum 
et al., 2012), and by the principle researcher. The participants source of the knowledge and 
whether or not they had used a generic medicine were also determined (Babar et al., 2010). 
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Perceptions on safety, efficacy and quality of generic medicines and of branded medicines were 
determined and compared in the data analysis (Bulsara et al., 2010). Different scenarios were 
included to determine participant choices for a generic or branded medicine (Babar et al., 2010), 
(Keenum et al., 2012). 
Influence of Healthcare professionals on participant use of generics was determined to help 
assess attitudes and perceptions (Babar et al., 2010). Attitudes were also determined by 
assessing participant considerations when selecting their medicines as well as the different 
choices made in different scenarios such as nature and severity of illness. 
2.3 Sample selection 
Sampling of Pharmacies – The Medpages (internet database for health professionals and 
practices) and the South African Pharmacy Council database of registered pharmacies was 
used to get an approximately complete list of all pharmacies in the Northern Johannesburg 
region. A random sample of pharmacies stratified by suburbs was taken aiming for a final 10% 
sample of pharmacies within northern Johannesburg (Holdsworth, 2012). This came up to a 
sample of nine pharmacies selected in the northern region of Johannesburg. It was assumed 
that all pharmacies sell and keep stocks of both generic and branded medicines. Requests to 
conduct research were sent out to the pharmacy owners on this list.  
Sampling of participants – the statistical programme Epi Info was used to calculate a sample 
size. Based on a 95% confidence interval, a precision (confidence limit) of 5% and an assumed 
expected frequency in favour of or against generics of 50%, a sample of at least 383 
participants was required. This figure was computed automatically by the Epi Info programme. 
An initial random sample of 400 participants was therefore targeted to be used. Questionnaires 
were administered to the initial random sample of 400 consumers visiting the randomly selected 
pharmacies (with consent from the pharmacy owner). (Wits statistician, 2012). 
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2.4 Pilot study 
The principle researcher conducted an initial pilot study by testing the questionnaire on a group 
of approximately 20 participants from the study population. Feedback received on structure 
sequence and clarity was incorporated into the final questionnaire which was used. Generally 
the main feedback was surrounding flow of the questionnaire. The questionnaire had been 
initially designed to allow data collection on the topical issues first followed by collection of 
demographic data at the end of the questionnaire. However during testing, most respondents 
felt that they would rather answer the simple demographic questions first and “ease into the 
more difficult questions” as opposed to answering the topical issues at the beginning. The flow 
of the questionnaire was therefore adjusted accordingly and demographic data were collected 
first. The research supervisors were consulted in revision of the questionnaire after the pilot 
study. 
2.5 Data collection methodology 
A station was set up in the private counselling area of the pharmacy (or such private area 
provided by the pharmacy). Every alternate consumer was approached and politely asked for a 
moment, either before they got their prescription or after, to talk about a study being conducted 
in the pharmacy.  
Upon reaching the private area set aside, the recruitment process began with the administration 
of the patient information leaflet and informed consent aided by a co-researcher. Willing 
customers became participants in the study provided they meet the inclusion criteria i.e. they 
needed to be between the ages of 18-70 years, able to communicate in English, and willing to 
participate. If the consumer declined to spare their time to go through the recruitment phase or 
to participate the next random consumer was approached and a note was made of the reason 
for declining as well as total number of consumers who declined per day.  
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The administration of all the questionnaires was performed by the Principal researcher. This 
allowed the Principal researcher to pick up on issues that are not possible to ascertain during 
the survey. 
2.6 Analysis of Data 
All questionnaires collected during the data collection process were included in the data 
analysis. There were no major changes made after the pilot study, so these 20 responses were 
included in the final data set. Fifteen participants decided to stop in the middle of the survey 
citing various reasons from not having time, having to deal with an emergency, and not feeling 
comfortable with divulging personal information. The total number of survey responses included 
in the data analysis came to 402 questionnaires. Creation of the Database and Data entry was 
performed using Microsoft Excel. Data analysis was carried out in SAS (SAS Institute Inc., SAS 
Software, version 9.3 for Windows, Cary, NC, USA: SAS Institute Inc. [2002-2010]).  
Descriptive statistical data was used to describe the demographics of the study group. The 5% 
significance level was used throughout, unless specified otherwise. The chi-squared (Χ2) test 
was used to assess the relationships between categorical variables. In particular, the chi 
squared test was used to show the relationships that exist between responses to the questions 
covering knowledge, attitudes and perception versus the responses to the explanatory 
questions which included questions on demographics. Fisher’s exact test was used for 2 x 2 
tables or where the requirements for the Χ2 test could not be met. The strength of the 
associations was measured by Cramer’s V and the phi coefficient respectively (Gaylard, 2013). 
For Cramer’s V and the phi coefficient, the following scale of interpretation was used: 
0.50 and above  high/strong association 
0.30 to 0.49  moderate association 
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0.10 to 0.29 weak association 
 
below 0.10 little if any association 
Only Cramer’s V values below 0.10 that show little or no association between variables were not 
included in the results and discussion. The remaining Cramer’s V ranges were considered 
important enough to include in the results and discussion sections. 
To compare the responses between perception on safety of generic medicines and perception 
on safety of branded medicines as well as the responses between perception on quality of 
branded medicines and perception on quality of generic medicines, Bowker’s test of symmetry 
was used.  
For Bowker’s test of symmetry, the following scale of interpretation was used: 
 Bowker’s test of symmetry is significant at (p<0.0001) 
 If the test is non-significant, it indicates that the cell proportions in the cross-tabulation of 
the ratings of the two questions are symmetric, or that pij = pji for all pairs of table cells.  
 If the test is significant it means that the respondents are selecting the categories in 
differing proportions for the two questions being compared (Gaylard, 2013). 
2.7 Study limitations 
Ideally in addition to the questionnaire, a focus group discussion needed to be conducted to 
gain better insights on the consumer perception, attitudes, and knowledge. However this was 
not possible due to resource constraints. 
The structure of the questionnaire consisted mostly of closed ended questions and this may 
have limited consumer responses.
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2.8 Ethical considerations 
Ethics approval for this research was granted by the University of the Witwatersrand, Human 
Research Ethics Committee (HREC). Participation in the study occurred only after going 
through a comprehensive informed consent process. All information obtained during the course 
of the study including personal data and research data were kept strictly confidential and stored 
in an access controlled environment.  
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CHAPTER 3 - RESULTS 
3.1 Results and Analyses 
3.1.1 Demographic characteristics of the study group  
The demographics of the sample are tabulated in Table 3. “Number of respondents” refers to 
the number of respondents counted for the variable measured. “Percent” refers to the 
expression as a percentage of the number of respondents of each variable divided by the total 
for the sub group of demographic data. 
Table 3 - Demographics 
Demographic variable  Number of respondents Percent % 
Pharmacy 
A 32 8.0 
B 45 11.2 
C 45 11.2 
D 45 11.2 
E 45 11.2 
F 45 11.2 
G 45 11.2 
H 45 11.2 
I 55 13.7 
Age 
18-29y 106 26.4 
30-39y 128 31.8 
40-49y 92 22.9 
50y+ 76 18.9 
Gender 
Male 165 41.0 
Female 229 57.0 
Missing 8 2.0 
Race 
Black 192 47.8 
White 157 39.1 
Indian 33 8.2 
Coloured 17 4.2 
Asian 2 0.5 
Missing 1 0.3 
Education None 1 0.3 
Primary incomplete 3 0.8 
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 Number of respondents Percent 
Primary complete 8 2.0 
Secondary incomplete 49 12.2 
Secondary complete 
 166 41.3 
Tertiary 
 175 43.5 
English language skill 
Poor 10 2.5 
Good 119 29.6 
Very Good 46 11.4 
Excellent 226 56.2 
Household Income 
< R10k 85 21.1 
R10-20k 123 30.6 
R20-25k 61 15.2 
> R25k 132 32.8 
Missing 1 0.3 
Health Insurance 
(medical aid) 
Not insured 138 34.3 
Comprehensive 244 60.7 
Hospital plan 15 3.7 
Formulary drugs + hospital 
plan 5 1.2 
Who pays for health 
insurance (medical 
aid) 
Self 203 50.5 
Employer 11 2.7 
Part self-part employer 50 12.4 
Not insured 138 34.3 
Health insurance 
(medical aid) group 
Not insured 138 34.3 
Comprehensive: self 185 46.0 
Comprehensive: employer/part 59 14.7 
Hospital plan 20 5.0 
Number of visits to the 
pharmacy 
Once in while 157 39.1 
At least once a month 190 47.3 
Several times per month 45 11.2 
At least once per week 7 1.7 
Several times per week 3 0.8 
Number of prescription 
medications currently 
taken 
None 248 61.7 
1-5 150 37.3 
More than 5 4 1.0 
Number of chronic 
medications currently 
taken 
None 304 75.6 
1-5 96 23.9 
More than 5 2 0.5 
The following can be noted from Table 3:  
Demographic variable                                                               Number of respondents Percent % 
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3.1.1.1 Sample distribution by pharmacy 
The sample was well spread across the nine pharmacies selected for the study. 
3.1.1.2 Age distribution 
The frequency distribution of respondent ages indicates that the bulk of the sample was aged 
below 50 years. The elderly population had a lower representation in the sample. The ages 
were categorised into four categories. 
3.1.1.3 Gender distribution 
The sample showed a slight but significant predominance towards females (57%; p=0.0012). 
3.1.1.4 Racial distribution 
The group Asian was excluded from further analyses involving Race as it was too low. 
3.1.1.5 Level of education 
The lowest four groups were combined for further analysis. 
3.1.1.6 English language skill 
Approximately 97% of the sample had good to excellent English language skills which allowed 
for ease of communication and the correct comprehension of the survey questions. 
3.1.1.7 Household income 
The sample was fairly well spread across the given categories of household income (HHI). The 
highest income group in this sample was the group earning greater than R 25 000 per month 
which was 32.8% of the sample. The trend of high earners was expected for this sample as 
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residents in the Northern suburbs are generally known to be in the higher income brackets 
(Average urban household income, 2010). 
3.1.1.8 Health insurance (medical aid) status and funding method 
Over 60% of the respondents had comprehensive health insurance (medical aid), while a further 
34% were not insured at all.  A very low proportion (5%) had a hospital plan of some kind. 51% 
of respondents self-funded their health insurance (medical aid). Cross-tabulation of Health 
Insurance and Health insurance funding method produced four health insurance types for 
further analysis as defined. 
o Not insured, Comprehensive: self-funded, Comprehensive: fully or partly employer-
funded, Hospital plan 
3.1.1.9 Frequency of visits to a pharmacy and medicine use 
The majority of respondents visited a pharmacy at least one a month (47.3%).  13.7% of the 
respondents purported to visit a pharmacy several times per month or more and the remaining 
39.1% visited at least once every month. 38.3% of the respondents were on at least one 
prescription medicine at the time of the survey whilst 24.4% were on chronic medications.  The 
statistics on frequency of pharmacy visits combined with the statistics on prescription and 
chronic drugs taken predict a relatively high level of medicine use in this population.  
Cross-tabulation of demographic variables with each other 
The demographic variables were then cross-tabulated with each other. Phi coefficients were 
determined between two dichotomous variables and Cramer's V between two categorical 
variables. The results are tabulated in the spreadsheet (tab: Associations). Significant 
associations are marked (*: p<0.05; **: p<0.01). Now looking at the significant associations:  
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3.1.1.10 Age versus Number of medications:   
The proportion of respondents with one or more prescription medications increased with age, as 
did those with one or more chronic medications as shown in Figure 1. 
 
Figure 1 – Age versus number of medications 
3.1.1.11 Gender versus Number of medications   
There were a higher proportion of respondents with one or more prescription medications 
amongst females as shown in Figure 2. The same was true for chronic medications. 
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Figure 2 – Gender versus number of medications 
3.1.1.12 Race versus Household income (HHI):  
In this sample, the White respondents tended to have a HHI in the higher categories compared 
to Black respondents as shown in Figure 3. 
 
Figure 3 – Race versus Household income 
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3.1.1.13 Race versus Health insurance (medical aid) (HI) status   
There were a higher proportion of non-insured respondents, and a lower proportion of 
Comprehensive self-insured respondents, in the Black group compared to the White group as 
well as the other minor groups in this population (see Figure 4). 
  
Figure 4 -- Race versus Health insurance (medical aid) (HI) status 
3.1.1.14 Race versus Pharmacy visits and Medication use 
Respondents in the Black group visited the pharmacy less frequently than those in the White 
group (see Figure 5). 
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Figure 5 – Race versus pharmacy visits 
The proportion of respondents who used one or more prescription medications was higher for 
the White group than for the other groups; the same was true for chronic medications (see 
Figure 6). 
 
Figure 6 – Race versus Medication use 
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3.1.1.15 Household income (HHI) versus Health insurance (medical aid) (HI) status  
The higher the income bracket, the more likely the respondents were to be comprehensively 
insured. Non-insurance also tended to decrease with higher income (see Figure 7 and Table 4).  
 
Figure 7 – Household income versus Health insurance (medical aid) status 
Table 4: Cross-tabulation of Household income and Health insurance (medical aid) group 
Table of HHI by HI Group 
HHI HI Group 
  Not insured Comprehensive: 
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Comprehensive: 
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< R10k 88.24 4.71 3.53 3.53 
R10-20k 36.07 41.8 18.03 4.1 
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> R25k 9.92 70.23 13.74 6.11 
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3.1.1.16 Household income (HHI) versus pharmacy visits and medication use  
The frequency of pharmacy visits generally increased with increasing HHI. The proportion of 
respondents who used one or more prescription medications increased with increasing HHI; the 
relationship for chronic medications was, however, not significant (presumably because these 
are less ‘optional’) (see Figure 8). 
 
Figure 8 – Household income versus medication use 
3.1.1.17 Health insurance (medical aid) (HI) status versus pharmacy visits and medication 
use 
The trends were as expected based on whether or not the respondents are paying for the 
medications themselves or not. Those not insured tended to visit a pharmacy less frequently 
(54.3%; p<0.05, of uninsured respondents selected the option “once in a while” when asked 
how often they visit the pharmacy). The group of comprehensively insured respondents had the 
highest frequency of pharmacy visits (see Figure 9). 
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Figure 9 - Health insurance (medical aid) (HI) status versus pharmacy visits 
The proportion of respondents who used one or more prescription medications was higher for 
those who were insured than for those who were not. The proportion of respondents who used 
one or more chronic medications was higher for those on comprehensive plans than for those 
who were not (see Figure 10). 
 
Figure 10 – Health insurance (medical aid) versus medicine use 
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The proportion of respondents who used one or more prescription medications was higher for 
those who visited the pharmacy more often – as might be expected.  The same was true for 
chronic medications (see Figure 11). 
 
Figure 11 – Frequency of pharmacy visits versus medication use pattern 
In summary, there were few unexpected relationships between the demographic variables. 
Race, education, Household hold income and English language skills were closely related, as is 
almost always the case in a sample of the general SA public (Statistics South Africa, 2012). 
These factors in turn influenced Health Insurance status, frequency of pharmacy visits and 
medication use patterns. 
3.1.2 Knowledge of generics 
3.1.2.1 What is a generic medicine?  
To assess their knowledge on generics, respondents were asked the question “what is a 
generic medicine?” The responses to this question are tabulated in Table 5. 
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Table 5: Overall responses to the question “what is a generic” 
 
% yes 
Cheaper medicine 43.6 
Same active medicine as the 
original, with a different name 
34.4 
Similar medicine to the original 30.3 
Not sure 5.4 
Another brand 1.3 
Better medicine than the original 0.0 
The proportion of respondents who chose each of the options is also shown graphically in figure 
12:  Note that the percentages do not sum to 100% since more than one option could be 
chosen.  The responses were fairly evenly divided between the top three responses as shown in 
Figure 12. 
 
Figure 12: Responses to the question “what is a generic” versus percentage of respondents 
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The responses or combinations of responses (where more than one response was chosen by a 
respondent) are shown in Table 6: 
Table 6: Combinations of responses to the question “what is a generic” 
Cheaper 
medicine 
Same active 
medicine as the 
original, with a 
different name 
Similar 
medicine to 
the original 
Not 
sure 
Another 
brand 
Better 
medicine 
than the 
original 
n % of 
respondents 
0 0 0 0 0 0 1 0.3 
0 0 0 0 1 0 2 0.5 
0 0 0 1 0 0 21 5.3 
0 0 1 0 0 0 94 23.5 
0 0 1 0 1 0 2 0.5 
0 1 0 0 0 0 98 24.5 
0 1 1 0 0 0 11 2.8 
1 0 0 0 0 0 131 32.8 
1 0 1 0 0 0 14 3.5 
1 1 0 0 0 0 20 5.0 
1 1 1 0 0 0 5 1.3 
1 1 1 0 1 0 1 0.3 
Key: 0 – denotes non-selection; 1 – denotes selection 
Most commonly respondents were only able to define a generic medicine as a “cheaper 
medicine” (32.8%). Only 24.5% of the respondents were able to correctly define a generic 
medicine as a medicine with the same active as the original but with a different name. However, 
these respondents were unable to add that it is also a cheaper medicine for a more complete 
definition. Another group of respondents (23.5%) defined a generic medicine as a similar 
medicine to the original without making the distinction of it having the same active ingredient.  
Only 5% of the respondents were able to most accurately describe a generic medicine as one 
that has the same active medicine as the original with a different name as well as being a 
cheaper medicine.  
Combining the respondents who were able to define a generic medicine only as a medicine with 
the same active as the original but with a different name (n=98) with those who chose to define 
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generic medicine both as a medicine with the same active medicine as the original with a 
different name as well as being cheaper (n=20), it can be inferred that only 118 respondents 
from the sample of 400 (29.5%) had a reasonable to good understanding of what a generic 
medicine actually is. 
None of the respondents thought a generic medicine was a better medicine than the original. 
The following significant association’s with respect to the top three definition choices vs. the 
demographic variables were found (see Table 6 for the top three definition choices as shown by 
the highest percentage of selection by respondents): 
Cheaper medicine 
 Health insurance (medical aid) status (p=0.037; Cramer’s V=0.15): those on part-funded 
comprehensive Health insurance were less likely to indicate that a generic was a 
cheaper medicine than those not insured or on other health insurance plans. 
Similar medicine (The data below is derived from the association performed between data on 
“Similar medicines” as presented in table 6 (page 57) and data on demographics as presented 
in section 3.1.1. (page 44). 
 Education (p=0.041; Cramer’s V=0.13): those with ‘none to secondary incomplete’ 
education were less likely to indicate that a generic was a similar medicine than those 
with higher levels of education. 
 HHI (p=0.041; Cramer’s V=0.13): those in the lowest HHI category were less likely to 
indicate that a generic was a similar medicine than those with higher HHI. 
 Number of visits to the pharmacy (p=0.032; Cramer’s V=0.13): those with fewer 
pharmacy visits (once in a while) were less likely to indicate that a generic was a similar 
medicine than those with more frequent pharmacy visits. 
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Same active medicine with different name 
 Education and English language skill: Those with tertiary education were more likely to 
select this answer than those with lower levels of education (p=0.015; Cramer’s V=0.15). 
Those with excellent English skills were also more likely to select this answer than those 
with poorer English skills (p=0.0060; Cramer’s V=0.16).    
 Household Income (HHI): The proportion of respondents who selected this answer 
increased with increasing HHI (p=0.014; Cramer’s V=0.16).   
 Number of medications taken: Those with one or more prescription medications were more 
likely to select this answer than those without (p=0.0018; Cramer’s V=0.16). 
3.1.2.2 Sources of information regarding generics 
To ascertain where they get their information on generics from, respondents were asked about 
their sources of information regarding generics. Their responses are illustrated in Figure 13. The 
most common source of information was pharmacists, followed by doctors. Other sources 
played a minor role. 
 
Figure 13: Sources of information regarding generics 
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Most respondents only picked one source of information regarding generics. 
For items which had more than 5% response overall, the following significant associations with 
respect to the demographic variables were found (see table 7 for results of the chi squared test 
performed to reveal the association between sources of information regarding generics versus 
demographic variables. Phi coefficients (p) and Cramer’s V values were then calculated to show 
the strengths of the associations): 
Pharmacist as a source of information regarding generics versus: 
 Age (p=0.022; Cramer’s V=0.16): the percentage of respondents who indicated pharmacists 
as a source of information increased with age. 
 Chronic medication use (p=0.025; Cramer’s V=0.11): the percentage of respondents who 
indicated pharmacists as a source of information was higher for those who were not on 
chronic medications. This corresponds with the below finding of the general tendency of 
chronic medication users to get information regarding their medicines from their doctors.
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Table 7: Associations between Sources of information regarding generics versus demographic variables 
% yes unless 
indicated 
otherwise 
 
Total Age Race Education HHI 
18-
29y 
30-39y 40-
49y 
50y+ Black White Colou
red 
Indian None to 
Secondary 
incomplete 
Secondary 
complete 
Tertiary < 
R10k 
R10-
20k 
R20-
25k 
> 
R25k 
Pharmacist 70.8 59.4 72.4 76.7 76.3 71.7 71.2 76.5 60.6 75.4 75.2 64.9 80.0 70.0 71.4 65.1 
Doctor 39.0 39.6 36.6 38.9 42.1 34.2 42.9 29.4 51.5 26.2 37.3 45.2 28.2 44.2 32.1 44.2 
Other Health 
professionals 
 
2.3 2.0 2.4 1.1 3.9 1.1 2.6 . 9.1 . 0.6 4.8 . 2.5 1.8 3.9 
Internet 16.9 21.8 19.5 14.4 9.2 9.8 25.6 11.8 18.2 4.9 17.4 20.8 8.2 5.8 21.4 31.0 
Magazines or 
newspapers 
 
7.9 7.9 11.4 7.8 2.6 9.2 5.8 17.6 6.1 3.3 6.8 10.7 3.5 10.0 7.1 9.3 
Family and 
friends 
 
5.4 9.9 2.4 2.2 7.9 4.3 6.4 11.8 3.0 6.6 5.0 5.4 3.5 7.5 5.4 4.7 
Cont. Table 7: Associations between Sources of information regarding generics versus demographic variables 
% yes unless indicated 
otherwise 
 
Total HI Group Number of visits to a 
pharmacy 
Number of 
Prescription 
medicines taken 
 
Number of Chronic 
medications taken 
< 
R10k 
Not 
insured 
Comprehe
nsive: self 
Compreh
ensive: 
employer/
part 
Hospital 
plan 
Once in 
while 
At least 
once a 
month 
Several times 
per month or 
more 
None 1 or 
more 
None 1 or 
more 
Pharmacist 70.8 80.0 76.6 68.5 64.3 68.4 70.4 74.9 58.2 70.8 70.7 73.8 61.5 
Doctor 39.0 28.2 27.7 43.3 55.4 31.6 34.9 40.4 45.5 38.8 39.3 34.4 53.1 
Other Health 
professionals 
2.3 . 2.2 2.8 1.8 . 2.6 1.6 3.6 2.5 2.0 2.4 2.1 
Internet 16.9 8.2 7.3 24.2 17.9 15.8 11.2 18.0 29.1 13.3 22.7 17.0 16.7 
Magazines or 
newspapers 
7.9 3.5 6.6 7.9 10.7 10.5 10.5 5.5 9.1 8.8 6.7 9.2 4.2 
Family and friends 5.4 3.5 8.0 2.2 7.1 10.5 4.6 4.4 10.9 6.3 4.0 5.8 4.2 
NB: Highlighted portions indicate areas of significant association
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Doctor as a source of information regarding generics versus: 
 Education (p=0.033; Cramer’s V=0.13): the percentage of respondents who indicated 
doctors as a source of information increased with the level of education.   
 HHI and HI Group: the percentage of respondents who indicated doctors as a source of 
information increased with the level of HHI, although the trend was not very clear (p=0.043; 
Cramer’s V=0.14) and was higher for those on comprehensive plans (p=0.043; Cramer’s 
V=0.14).   
 
Figure 14: Doctor as a source of information regarding generics versus Health insurance 
(medical aid) group 
 Chronic medication use (p=0.0010; Cramer’s V=0.16): the percentage of respondents who 
indicated doctors as a source of information was higher for those with one or more chronic 
medications.   
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 Race (p=0.0015; Cramer’s V=0.20): the percentage of respondents who indicated internet 
as a source of information was higher for Whites and Indians, compared to Blacks and 
Coloureds. 
 
Figure 15: Internet as a source of information regarding generics versus Race 
 Education and English language skill: The percentage of respondents who indicated internet 
as a source of information increased with the level of education (p=0.014; Cramer’s V=0.15) 
and increased with the level of competence in English (p<0.0001; Cramer’s V=0.26). 
 HHI and HI Group: The percentage of respondents who indicated internet as a source of 
information increased with HHI (p<0.0001; Cramer’s V=0.29) and was higher for the insured 
groups, particularly for the comprehensive self-insured group (p=0.0009; Cramer’s V=0.20). 
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Figure 16: Internet as a source of information regarding generics versus Health insurance 
(medical aid) group 
 Number of visits to a pharmacy and number of prescription medicines currently taken: The 
percentage of respondents who indicated internet as a source of information increased with 
increasing frequency of visits to the pharmacy (p=0.0063; Cramer’s V=0.16) and was higher 
for those with one or more prescription medications (p=0.014; Cramer’s V=0.12).  
Family/friends as a source of information regarding generics versus: 
 Age (p=0.017; Cramer’s V=0.16): the percentage of respondents who indicated 
family/friends as a source of information was higher at both ends of the age range. 
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Figure 17: Family/friends as a source of information regarding generics versus Health insurance 
(medical aid) group 
3.1.2.3 Do you think using generic medicines can save on drug costs? 
To assess their knowledge on the cost saving ability of generics, respondents were asked 
whether they thought generics can save on drug costs. Overall, 86% of the respondents agreed 
that using generics medicines can save on drug costs, while 6% disagreed and 7% indicated 
that they did not know if generics can save on drug costs or not. 
The following significant associations with respect to the demographic variables were found: 
 Race (p=0.0057; Cramer’s V=0.15): the level of agreement was higher amongst Whites than 
Blacks  
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Figure 18: Level of agreement with cost saving ability of generics versus race 
 Education and English language skill: The level of agreement was lower for the lowest 
education category (p=0.0047; Cramer’s V=0.14) and the level of uncertainty (DK) was 
higher for the two lower English skill categories (p=0.0020; Cramer’s V=0.17). 
 HHI and HI group: The level of agreement was lower for the lowest HHI category (p=0.0003; 
Cramer’s V=0.18) and the level of agreement was also lower for the uninsured group 
(p<0.0001; Cramer’s V=0.19). 
 Number of visits to a pharmacy (p<0.0001; Cramer’s V=0.18): the level of agreement was 
lower for those who visited the pharmacy ‘once in a while’. 
 Number of Prescription medicines and Number of chronic medicines: The level of 
agreement was higher for those who had one or more prescription medications (p=0.0072; 
Cramer’s V=0.16) and for those who had one or more chronic medications (p=0.018; 
Cramer’s V=0.14). 
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3.1.3 Attitudes  
Certain questions were specifically asked to assess attitudes. The results of the responses to 
these questions are presented below. 
3.1.3.1 Do you use generic medicines?  
Overall, 78% of the respondents indicated that they used generic medicines, while 20% said 
they did not and 2% indicated that they did not know. 
The following significant associations with respect to the demographic variables were found: 
 Education (p<0.0001; Cramer’s V=0.18): the level of agreement was lower for the highest 
education category. 
3.1.3.2 When you buy medication, do you consider who manufactured it? Are there 
certain manufacturers you tend to trust more than others?  
The responses to the above questions are shown below.  It appears that the majority of 
respondents neither considered nor trusted certain manufacturers when purchasing medications 
as they mostly chose the answer ‘no’ to the questions. 
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Figure 19: Consideration and trust of certain manufacturers when purchasing medicines 
The following significant associations with regards to the demographic variables were found: 
Consideration of manufacturer when purchasing medicine: 
 Race (p=0.0028; Cramer’s V=0.16): the level of consideration of manufacturers was higher 
amongst Whites (and Indians) than Blacks (and Coloureds). 
 Education and English language skill: the level of consideration of manufacturers increased 
with increasing level of education (p<0.0001; Cramer’s V=0.19). The level of consideration 
of manufacturers also increased with increasing level of English skill (p=0.036; Cramer’s 
V=0.11). 
 HHI and HI Group: the level of consideration of manufacturers increased with increasing 
HHI, although the trend was not very clear (p=0.041; Cramer’s V=0.13). The level of 
consideration of manufacturers was much lower amongst those not insured (p=0.0027; 
Cramer’s V=0.16). 
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Manufacturer trust:   
Race (p=0.0033; Cramer’s V=0.13): the level of consideration of trust in manufacturers was 
higher amongst Whites (and Indians) than Blacks (and Coloureds). 
 Education and English language skill: the level of consideration of trust in manufacturers 
increased with increasing level of education (p<0.0001; Cramer’s V=0.24) and also 
increased with increasing level of English skill (particularly from poor/good to the higher 
categories) (p=0.032; Cramer’s V=0.12). 
 HI Group (p=0.0002; Cramer’s V=0.18): the level of consideration of trust in manufacturers 
was much lower amongst those not insured. 
3.1.3.3 Choice of medication for minor illness 
When asked on their medication choices in the event of a minor illness, the most popular choice 
was generics (41%), followed by brand, prescription and cheapest. The proportion of 
respondents who chose each of the options is shown below:  Note that the percentages do not 
sum to 100% since more than one option could be chosen.  
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Figure 20: Choice of medication in minor illness 
3.1.3.4 Choice of medication for major illness 
Trends changed when the respondents were asked about their medication choices in the event 
of a major illness. The proportion of respondents who chose each of the options is shown 
below:  Here the selections were fairly evenly split between choosing exactly what is on the 
prescription and choosing the brand medication.  Generics were chosen by only 10% of the 
respondents. 
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Figure 21: Choice of medication in major illness 
3.1.3.5 Choice of medication for chronic illness 
The proportion of respondents who chose each of the options is shown below: Here the majority 
choice was to go for exactly what is on the prescription, with other options given little support. 
Generics were chosen by only 5% of the respondents. This suggests most of the power on 
medication choices for chronic patients in this sample lies in the hands of the prescriber. 
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Figure 22: Choice of medication in chronic illness. 
3.1.3.6 Comparison of choice of generic, brand and prescribed medicine for minor, major 
and chronic illness 
The relative choice of brand, generic or exact prescribed medicine in the treatment of minor, 
major and chronic illness was considered. The data may be summarised graphically as follows: 
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Figure 23: Illness type versus medication choice 
All proportions within and between illness types are significantly different (p<0.0001), except the 
proportion of respondents who would choose brand and prescription medicines for major 
illnesses. 
For minor illnesses, the ratio of generic to brand use was 2.0:1, while for major and chronic 
illnesses, the ratio of generic to brand use was 0.33:1 and 0.42:1 respectively. This shows a 
significant shift in respondents attitudes towards generic medicines as the nature of their illness 
changed. 
The use of generics decreased with increasing illness severity, while the opposite was true for 
the selection of exactly what was prescribed.  The majority of respondents (54.7%) tended to 
put their trust in the prescriber the most when they made medication choices for chronic illness. 
The use of branded medicines (29.4%) was highest for major illnesses.  
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3.1.3.7 Results of the cross-tabulation of the main choices for the questions on attitudes:   
Associations between each pair of variables within the attitude questions - Phi coefficients 
for Fisher’s exact test were determined between each pair of variables. The results are 
tabulated in the spreadsheet. Significant associations are marked (*: p<0.05; **: p<0.01).  The 
results can be summarised as follows (see the cross-tabulations in Table 8 to understand the 
results): 
Table 8: Phi coefficients of the cross-tabulation of the main choices for the questions on 
attitudes 
 
Major illness Chronic illness 
Minor illness Prescription Brand Pharmacist Prescription Brand Pharmacist 
Generic -0.32** 0.16** 0.08 -0.01 0.02 0.07 
Brand -0.03 0.24** -0.02 -0.04 0.20* -0.05 
Prescription 0.52** -0.25** -0.10* 0.26** -0.10* -0.18** 
Cheaper one -0.13** -0.05 0.07 -0.11* -0.10* 0.17** 
 
 Those who chose their medication based on their prescription for a minor illness, were likely 
to do so too for major and chronic illnesses. 
 Those who chose their medication based on their prescription for a major illness, were likely 
to do so too for chronic illnesses. 
 Those who did not choose their medication based on brand for a minor illness, were unlikely 
to do so for major and chronic illnesses. 
 Those who did not choose their medication based on brand for a major illness, were unlikely 
to do so for chronic illnesses. 
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 Those who did not choose their medication based on pharmacist’s advice for a major illness, 
were unlikely to do so for chronic illnesses. 
 The major and chronic illness choices for those who chose generics for minor illnesses were 
not clear, i.e. they chose different options. 
Associations between attitudes and demographic variables - The following significant 
associations with regards to the demographic variables were found: 
a) Choice of medication in minor illnesses 
i) Generics 
 Race (p=0.016; Cramer’s V=0.16): A higher proportion of White (and Coloured) respondents 
had selected this option, compared to Black (and Indian) respondents. 
 English language skill (p=0.0098; Cramer’s V=0.15): the level of choice of this option was 
much higher for the Excellent category than for the other categories. 
 HHI (p=0.0098; Cramer’s V=0.17): the level of choice of this option was much lower for the 
lowest income group.   
ii) Brand 
 Race (p=0.0038; Cramer’s V=0.18): A higher proportion of Indian respondents had selected 
this option, compared to the other respondents. 
iii) Cheaper one 
 Race (p=0.0009; Cramer’s V=0.20): A higher proportion of Black respondents had selected 
this option, compared to the other respondents. 
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 Education and English language skill: The level of choice of this option increased with 
decreasing level of education (p=0.0034; Cramer’s V=0.17) and was much higher for the 
lowest English skill category (p<0.0001; Cramer’s V=0.22). 
 HHI and HI Group: The level of choice of this option increased with decreasing HHI 
(p=0.0005; Cramer’s V=0.21) and was highest for those not insured; and not chosen at all 
for those on a hospital plan (p=0.0044; Cramer’s V=0.18). 
iv) Prescription 
 Age (p=0.024; Cramer’s V=0.15): A higher proportion of the youngest and oldest age groups 
had selected this option, compared to the other two age groups which would suggest a 
higher dependence on the prescriber amongst the younger inexperienced respondents and 
the older respondents who are more likely chronic patients. 
 HHI (p=0.0056; Cramer’s V=0.18): the level of choice of this option decreased with 
increasing HHI.   
In summary the demographics of Race and HHI appear to be the common theme across the 
medication choices in minor illness; their effects are summarised in Figure 24 and 25. 
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.    
Figure 24: Race versus medication choice in minor illness 
As shown in Figure 24 there was a greater preference for all except the Indian racial group to 
select generic medicines over brand medicines in the case of a minor illness. Indians showed a 
greater preference for brand medicines than generics for minor illness. Overall, the greatest 
tendency for generic medicine use in minor illnesses was shown by the white and coloured 
group whilst the black group were the least likely racial group to use generics in minor illness.  
 
Figure 25: Household income versus medication choice in minor illness 
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As shown in table 8, those in the top two household income brackets (20-25k and >25k) were 
significantly more likely to select generic medicines over branded medicines in the case of a 
minor illness. Those in the lowest income group (<10k) were more likely to simply choose the 
cheapest option. Branded medicines were generally less popular in treating minor illnesses. 
b) Choice of medication in major illnesses 
i) Brand 
 Number of prescription medicines currently taken (p=0.019; phi coefficient=-0.12): A higher 
proportion those currently taking no prescription medications had selected this option, 
compared to those who were taking one or more prescription medications. 
ii) Prescription 
 Education (p=0.0023; Cramer’s V=0.17): A much lower proportion of those in the lowest 
education category selected this option, compared to those in the other education 
categories. 
 HHI and HI Group: the level of choice of this option was highest for the two middle HHI 
categories (10-20k, and 20-25k) (p=0.0034; Cramer’s V=0.15) and was highest for those 
respondents on Comprehensive plans and shown in Figure 26 (p=0.0078; Cramer’s 
V=0.17). 
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Figure 26: Health insurance (medical aid) group versus choice of exact prescribed 
medication 
 Number of chronic medicines currently taken (p=0.035; phi coefficient=0.11): A higher 
proportion of those currently taking one or more chronic medications had selected this 
option, compared to those who were taking no chronic medications. This is consistent with 
the results in minor illness and makes sense as there are other factors to consider for 
chronic patients such as the interactions between their chronic medications and other 
medications taken which their prescriber will know about.  
iii) Pharmacist’s advice 
 Education and HI Group: A higher proportion of those in the lowest education category 
selected that they would go with the pharmacists advice in medication choices for major 
illness, compared to those in the other education categories (p=0.043; Cramer’s V=0.13). 
The level of choice of this option was also highest amongst those not insured (p=0.0009; 
Cramer’s V=0.20). 
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 HHI (p=0.020; Cramer’s V=0.16): the level of choice of this option was highest for the lowest 
and highest HHI categories as shown in Figure 27. 
 
Figure 27: Household income versus decision to go with Pharmacist’s advice in medication 
choice for major illness 
 Number of chronic medications currently taken (p=0.047; phi coefficient=-0.10): A lower 
proportion of those currently taking one or more chronic medications had selected this 
option, compared to those who were taking no chronic medications. 
iv) Generic  
Even though there was less than 10% use of generic medicines in major illness, the following 
significant associations were found. 
 HI group: The level of choice of the generic option was highest amongst those on hospital 
plans (p=0.029; Cramer’s V=0.15). 
 Perception of effectiveness: (p=0.0085; Cramer’s V=0.16): The proportion of respondents 
who indicated they perceived generics to be more/as effective than/as branded medicines. 
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In summary, the demographic variables of HHI and HI Group appear to be the common theme 
(at least for Prescription and Pharmacist advice); their effects are summarised in Figure 28 and 
29. 
  
Figure 28: Household income versus medication choice for major illness 
As shown in Figure 28 on medicine choices in the event of a major illness, respondents had a 
general tendency to select branded medicines to the same extent regardless of household 
income. There was also a greater tendency to pick exactly what was on their prescription. 
Prescribers had an overall greater influence than Pharmacists and their greatest influence was 
on the higher income groups particularly in second to highest income group (20-25k), where 
there was the greatest tendency to rely on the prescriber (42.1%) and the least tendency to go 
with the pharmacists advice (8.8%) in choosing medication. Pharmacists had their greatest 
influence on the lowest income group (22.1%) but also had a significant influence (17.1%) on 
the highest income group (>25k). 
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Figure 29: Health insurance (medical aid) group versus medication choice for major illness 
As shown above, those comprehensively insured and paying for their own health insurance had 
the highest tendency (31.3%) to select brands in major illness. Generally, those on 
Comprehensive insurance plans regardless of payment method had a greater tendency to 
select exactly what was prescribed for the treatment of major illness. Those on Hospital plans 
selected brands and the exact prescribed medicine the least (21.1%). 
The Prescriber had a significantly greater influence than the Pharmacist on medicine choice 
amongst the insured groups. The influence of the Pharmacist on medication choices in major 
illness was generally low amongst respondents that were on some form of Health insurance. 
Only the uninsured respondents (24.1%) had a significant tendency to seek pharmacist advice 
on medicine choice in major illness but this group also had the second highest tendency 
(29.2%) to go with the brand medicine. 
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c) Choice of medicine in chronic illnesses 
i) Brand 
 Age (p=0.018; Cramer’s V=0.16): the level of choice of this option was highest amongst the 
youngest age group. 
 Education (p=0.034; Cramer’s V=0.13): the level of choice of this option was highest 
amongst two higher education groups. 
ii) Prescription 
 HI Group (p=0.0009; Cramer’s V=0.20): the level of choice of this option was highest for 
those respondents on Comprehensive self-insured plans. 
 
Figure 30: Health insurance (medical aid) group versus choice of prescribed medicine in chronic 
illness 
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 Race (p<0.0001; Cramer’s V=0.27): A higher proportion Black than White respondents 
selected this option. 
 Education and English language skills: A higher proportion of those in the lowest education 
category selected this option, compared to those in the other education categories 
(p=0.0002; Cramer’s V=0.20). The level of choice of this option decreased with increasing 
English skill (p=0.0053; Cramer’s V=0.16). 
 HHI and HI Group: The level of choice of this option decreased with increasing HHI 
(p=0.0013; Cramer’s V=0.20) and was highest amongst those not insured (p<0.0001; 
Cramer’s V=0.34). 
 Number of chronic medicines currently taken (p<0.0001; phi coefficient=-0.21): A lower 
proportion of those currently taking one or more chronic medications had selected this 
option, compared to those who were taking no chronic medications. 
iv) Generic  
Even though there was less than 10% use of generic medicines in chronic illness, a significant 
association exists between generic medicine use and the following demographic variables: 
 Race (p=0.0053; Cramer’s V=0.18): A higher proportion Indian respondents selected this 
option. 
 Number of visit to a pharmacy (p=0.0022; Cramer’s V=0.18): the level of choice of this 
option was highest amongst those with multiple visits to the pharmacy. 
 Number of chronic medicines currently taken (p=0.0065; Cramer’s V=0.14): the level of 
choice of this option was highest amongst those with one or more chronic medicines 
compared to those who were not taking any chronic medications. 
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 Perception of safety (p=0.031; Cramer’s V=0.15): The proportion of respondents who 
indicated they would they would choose generics was higher for those who perceived 
generics to be “very safe”. 
3.1.4 Perceptions  
Certain questions were asked to determine respondent’s perceptions. The responses to the 
perception questions are given below. 
3.1.4.1 Perception on safety of generic medicines and branded medicines  
As shown in Figure 31, overall 80% of the respondents indicated that they thought generic 
medicines were safe or very safe, while 95% of respondents thought that branded medicines 
were safe or very safe. 
 
Figure 31: Perception on safety of generic and branded medicines 
To compare the responses between perceptions on generic safety versus brand safety, 
Bowker’s test of symmetry was used. If the test is non-significant, it indicates that the cell 
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proportions in the cross-tabulation of the ratings of the two questions are symmetric, or that pij = 
pji for all pairs of table cells. If the test is significant it means that the respondents are selecting 
the categories in differing proportions for the two questions being compared.   Bowker’s test of 
symmetry was significant (p<0.0001). The cross-tabulation (table 9) shows that, amongst those 
who thought branded medicines to be safe or very safe, there was a shift towards slightly more 
negative perceptions towards generic medicines. 
Table 9: Cross-tabulation of perceptions on safety of Generic versus Branded medicines  
(cell %) 
Perception on safety of 
generic medicines 
 
Perception on safety of branded medicines 
Very 
safe 
Safe Moderately 
safe 
Not 
safe 
DK Total 
Very safe 10.53 3.01 0 0 0 13.53 
Safe 30.33 34.34 1.00 0 0.25 65.91 
Moderately safe 4.51 3.76 2.76 0 0 11.03 
Not safe 3.51 1.25 0 0 0 4.76 
Do not know (DK) 1.75 2.51 0 0 0.50 4.76 
Total 202 179 15 0 3 399 
50.63 44.86 3.76 0 0.75 100 
The following significant associations with regards to the demographic variables were found 
(Note the associations were performed based on data provided in section 3.1.4.1 versus the 
demographic data provided in 3.1.1): 
Association between Perceptions on safety of generic medicines versus demographic 
variables (excluding the response ‘do not know’): 
 Race (p=0.0005; Cramer’s V=0.16): Coloured and Indian respondents had a higher 
proportion of respondent who indicated “very safe” compared to White and Black 
respondents, who had a higher proportion of respondents who indicated “safe”. 
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 Education and English language skill: The proportion of respondents who indicated “very 
safe” compared to “safe” increased with level of education (p=0.0084; Cramer’s V=0.15) and 
the proportion of respondents who indicated “very safe” and “moderately safe” compared to 
“safe” increased with level of English skill (p=0.0029; Cramer’s V=0.14). 
 HI Group (p=0.022; Cramer’s V=0.13): The proportion of respondents who indicated “very 
safe” compared to “safe” was higher for the comprehensively insured groups. 
 Number of chronic medicines currently taken (p=0.0098; Cramer’s V=0.17): The proportion 
of respondents who indicated “very safe” compared to “safe” was higher for those using one 
or more chronic medications compared to those who were not. 
Association between Perceptions on safety of Branded medicines versus demographic 
variables (excluding ‘do not know’): 
 No significant associations with regards to any of the demographic variables were found. 
3.1.4.2 Perception on quality of branded medicines and generic medicines  
As shown in Figure 32, overall 64% of the respondents indicated that they thought generic 
medicines were of very good quality / good quality / same quality as other medicines, while 93% 
of respondents felt similarly about branded medicines. “Other medicines” meant other medicines 
on the market in general terms which may or may not be generics. 
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Figure 32: Perceptions on quality of generics versus brands 
To compare the responses between perceptions on quality of branded medicines and generic 
medicines, Bowker’s test of symmetry was used, which was significant (p<0.0001).  The cross-
tabulation (table 10) shows that, amongst those who thought branded medicines to be of good 
or very good quality, there was a shift towards slightly more negative perceptions towards 
generic medicines.  
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Table 10: Cross-tabulation of perceptions on quality of Generic versus Branded medicines  
(cell %) 
Quality of generics 
 
 
Quality of branded medicines 
Very 
good 
quality 
 Good 
quality 
Same as 
other 
medicines 
Moderate 
quality 
 Low 
quality 
DK Total 
Very good quality 12.25 1.75 0.50 0.50 1.00 0 16 
Good quality 15.75 16.75 0.50 0 0.25 0 33.25 
Same as other 
medicines 
2.50 3.50 8.25 0.50 0 0.25 15 
Moderate quality 7.50 9.50 0 2.00 0 0 19 
Low quality 9.75 0.75 0.25 0.25 1.00 0 12 
Do not know (DK) 1.25 2.25 0.25 0.25 0 0.75 4.75 
Total 196 138 39 14 9 4 400 
49.00 34.50 9.75 3.50 2.25 1.00 100 
The following significant associations with regard to the demographic variables were found: 
Associations between perceptions on quality of branded medicines versus demographic 
variables (excluding response ‘don’t know’): 
 English language skill (p=0.043; Cramer’s V=0.13): the proportion who indicated “very good 
quality” decreased and the proportion who indicated “same quality as other medicines” 
increased with increasing English language skill. 
 HHI (p=0.0006; Cramer’s V=0.17): the proportion who indicated “very good quality” 
decreased and the proportion who indicated “same quality as other medicines” increased 
with increasing HHI. 
 Race: As shown in Figure 33 below, all races had a significantly positive perception of the 
quality of brands. The option ‘very good quality’ and ‘good quality’ were used in significantly 
higher proportions than the options to describe brand quality. Blacks (53.8%) and Indians 
(60.6%) had the overall highest perception of brand quality.  
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Figure 33: Racial perceptions on Quality of branded medicines 
Associations between perceptions on quality of generic medicines versus demographic 
variables (excluding response ‘don’t know’): 
 Race (p=0.0056; Cramer’s V=0.16): combining the responses “very good quality” and “good 
quality” Indians had the overall greatest positive perception on quality of generics (see 
Figure 34) – the differences were more difficult to interpret compared to race versus brand 
perception. (The inter-racial perceptions on quality of generics versus brands are explained 
further in section 3.1.4.2.1). 
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Figure 34: Racial perceptions on Quality of generic medicines 
 HHI (p=0.0090; Cramer’s V=0.15): the proportion who indicated “same quality as other 
medicines” increased with increasing HHI as shown in Figure 35. 
 
Figure 35: Household income versus perceptions on quality of generic medicines 
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 HI Group (p=0.0029; Cramer’s V=0.16): see Figure 36 – the differences are difficult to 
interpret but it can be seen that the highest overall positive perception on quality of generics 
was amongst the comprehensively insured group who had part of their Medical Aid paid by 
their employers. Those on Hospital plans had the highest perception that generics are of 
moderate quality but none in this group felt that generics were of low quality. 
 
Figure 36: Health insurance (medical aid) group versus perceptions on quality of generic 
medicines 
 Number of prescription medicines currently taken (p=0.016; Cramer’s V=0.18): the 
proportion who indicated “same quality as other medicines” was higher for those who were 
using one or more prescription medications. 
 Number of chronic medicines currently taken (p=0.038; Cramer’s V=0.16): the proportion 
who indicated “very good quality” was higher for those who were using one or more chronic 
medications. 
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3.1.4.2.1 Racial comparison on perceptions of quality of generics versus brands 
To compare the perception of the quality of branded and generic medicines vs. race, the 
percentage of each racial group who rated each type of medicine as “very good quality” or 
“good quality” or “quality same as other medicines” was analysed (i.e. grouping ‘high quality’). 
The results are shown in Figure 37. 
 
Figure 37: Racial comparison on perceptions of quality of generics versus brands 
As shown in figure 37, the proportion of respondents who rated branded medicines as being of 
high quality was higher than the proportion of respondents who rated generic medicines as 
being of high quality, for each race group.  The disparity in perceptions of quality was widest for 
the Black and Indian groups. 
3.1.4.3 Perception on effectiveness of generic medicines compared to branded medicines  
As shown in Figure 38, 75% of respondents felt that generic medicines were as effective as 
branded medicines. There was a significant difference between the proportion of respondents 
who indicated generic medicines were ‘less effective’ and ‘as effective’ (p<0.0001). 
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Figure 38: Perceptions on effectiveness of generic medicines versus branded medicines 
No significant associations with regards to the demographic variables were found. 
3.1.4.4 Perceptions on side effects of generic medicines compared to branded medicines 
As shown in Figure 39, opinions were mixed, with 42% of respondents saying that generics 
have similar side effects to branded medicines, and 20% saying that generics have the same 
side effects. The difference between these two proportions was significant (p<0.0001). 15% 
indicated that branded medicines have less side effects (significantly less than the 20% who 
indicated that generics and brands have the same side effects; p=0.033). A further 21% did not 
know. More respondents felt branded medicines had fewer side effects (14.6%) than those who 
felt generics had fewer side effects (2.6%).  
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Figure 39: Perceptions on side effects of generic medicines compared to branded medicines 
The following significant associations with regards to the demographic variables were found 
(excluding DK): 
 Education (p<0.0001; Cramer’s V=0.22): as shown in Figure 40, those with higher levels of 
education were more likely to indicate that generics have the same (not similar) side effects 
and less likely to indicate that brands have less side effects than generics. 
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Figure 40: Education versus perceptions on side effects of generic medicines compared to 
branded medicines 
 Number of prescription medicines currently taken and number of chronic medicines currently 
taken: those taking one or more prescription medications had a higher proportion of 
respondents who indicated that generics had the same side effects as branded medications 
(p=0.0037; Cramer’s V=0.21). Those taking one or more chronic medications also had a 
higher proportion of respondents who indicated that generics had the same side effects as 
branded medications (p=0.024; Cramer’s V=0.17). 
3.1.5 Influences on patterns of generic medicine use  
Certain combinations of questions were cross-tabulated to analyse the influencers on generic 
use patterns. The results are given below.  
3.1.5.1 Perceptions and their influence on decision to use generic medicines 
The following significant associations were found from the cross-tabulation of the question “do 
you use generic medicine” with the perception questions: 
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a) Use of generic medicines versus perception of their safety (p<0.0001; Cramer’s 
V=0.41): The use of generic medicines increased with increasing perception of their safety 
as shown in table 11 and Figure 41. 
Table 11: Cross-tabulation of generic use versus perception of safety 
Cell % unless otherwise 
indicated 
Perception on safety of generics 
  
Very 
safe 
Safe Moderately safe Not safe 
Do you use generic 
medicines? 
        
Yes 87.3 87.8 50.0 31.6 
No 10.9 11.1 43.2 68.4 
As shown in table 11, the highlighted portions show a significant association between 
perception of safety and use of generics. 
 
Figure 41: Influence of perceptions about safety on generic medicine use 
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As shown in Figure 41, use of generics decreased as the perceptions on their safety became 
more negative. 
b) Use of generic medicines versus perception of quality (p<0.0001; Cramer’s V=0.35): as 
shown in the cross-tabulation below, the use of generic medicines was higher amongst 
those respondents who had positive perceptions of the quality of generics, compared to 
those who did not. 
Table 12: Cross-tabulation of generic use versus perception of quality 
Cell % unless 
otherwise indicated 
Perceived quality of generics 
  
 Very good 
quality 
Good 
quality 
Same as 
other 
medicines 
Moderate 
quality 
Low 
quality 
Do you use 
generic 
medicines? 
          
Yes 79.4 87.2 93.2 81.8 50.0 
No 19.0 11.3 3.4 18.2 50.0 
As shown in table 12, the highlighted portions reveal a significant association between the use 
of generics with the positive perceptions of their quality. Those who perceived the quality of 
generics to be the same as other medicines had the strongest association with the use of 
generics. 
 
c) Use of generic medicines versus perception of effectiveness (p<0.0001; Cramer’s 
V=0.46): as shown in Figure 42, the use of generic medicines was higher amongst those 
respondents who had positive perceptions of the effectiveness of generics, compared to 
those who did not. 
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Figure 42: Influence of perceptions about effectiveness on generic medicine use 
d) Use of generic medicines versus perceptions of side effects (p<0.0001; Cramer’s 
V=0.41): The use of generic medicines was higher amongst those respondents who thought 
generics had same / similar side effects, compared to those who did not as shown in Figure  
43. 
 
Figure 43: Influence of perceptions about side effects on generic medicine use 
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Other significant associations between perceptions and generic use patterns are as follows 
(Note the minor illness data is as provided in section 3.1.3.3 and Figure 20): 
e) Perception of safety versus choice of generics or brand in treatment of minor illness: 
The use of generic medicines in minor illness was associated with positive perceptions of 
their safety (p<0.0001; Cramer’s V=0.25). The use of brand medicines was associated with 
negative perceptions of the safety of generics (p<0.0001; Cramer’s V=0.35).  
f) Perception of quality of generics versus choice of generics or brands in treatment of 
minor illness: The use of generic medicines in minor illness was associated with the 
perception of equivalent quality of generics compared to other medicines (p=0.0007; 
Cramer’s V=0.22) as shown in Figure 44. The use of brand medicines was associated with 
perceptions that generics were of low quality (p<0.0001; Cramer’s V=0.40). 
       
Figure 44: Influence of perceptions about quality on generic medicine use in minor illness 
g) Perception of effectiveness of generics versus choice of generics or brands in 
treatment of minor illness: The use of generic medicines in minor illness was associated 
with equivalent perception of effectiveness of generics compared to other medicines 
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(p<0.0001; Cramer’s V=0.28). The use of brand medicines was associated with the 
perception of lower effectiveness of generics compared to other medicines (p<0.0001; 
Cramer’s V=0.41). 
h) Perception of side effects of generics versus choice of generics in treatment of minor 
illness: The use of generic medicines was associated with the perception of them having 
the same / similar / less side effects compared to other medicines (p=0.033; Cramer’s 
V=0.17). The use of brand medicines was associated with the perception that generics do 
not have the same / similar side effects compared to other medicines (p<0.0001; Cramer’s 
V=0.32). 
i) Perception of side effects of brands versus choice of generics in treatment of major 
illness. The use of brand medicines was associated with the perception that generics do not 
have the “same” side effects compared to other medicines (p=0.0015; Cramer’s V=0.22). 
3.1.5.2 The Pharmacist and their influence on generic use patterns 
Overall, 74% of respondents reported that their pharmacist did encourage them to use generics, 
while 4% did not know. 
The following significant associations were found: 
a) Effects of the Pharmacist encouraging generic medicine use on actual generic 
medicine use: (p<0.0001, Cramer’s V=0.25) There was a higher use of generics amongst 
those who reported that their pharmacists encouraged them to use generics, compared to 
those that reported that that the pharmacist did not encourage them to use generics as 
shown in Figure 45. 
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Figure 45: Influence of the pharmacist on generic medicine use 
b) Effects of Pharmacist encouraging generic medicine use on perceptions on safety of 
generic medicines (p=0.0015; Cramer’s V=0.20): The proportion of respondents who 
reported that pharmacists encouraged them to use generics increased with increasing 
positive perception of their safety. 
c) Effects of Pharmacist encouraging generic medicine use on perceptions on quality of 
generic medicines (p=0.0013; Cramer’s V=0.22): The proportion of respondents who 
reported that pharmacists encouraged them to use generics was higher amongst those 
respondents who had positive perceptions of the quality of generics, compared to those who 
did not. 
d) Effects of Pharmacist encouraging generic medicine use on the perception of 
effectiveness of generic medicines (p=0.017; Cramer’s V=0.15): The proportion of 
respondents who reported that pharmacists encouraged them to use generics was higher 
amongst those respondents who had positive perceptions of the effectiveness of generics, 
compared to those who did not. 
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e) Effects of Pharmacist encouraging generic medicine use on the perceptions on side 
effects of generic medicines (p=0.0051; Cramer’s V=0.20): The proportion of respondents 
who reported that pharmacists encouraged them to use generics was higher amongst those 
respondents who though generics had same / similar side effects, compared to those who 
did not. 
f) Pharmacist as a source of information regarding generics versus Pharmacist 
encouraging generic medicine use (p<0.0001; Cramer’s V=0.25): A higher proportion of 
those who quoted pharmacists as a source of information regarding generics, said that 
pharmacists had encouraged them to use generics, compared to those who had not quoted 
pharmacists as a source of information. 
g) Pharmacist as a source of information on generics versus choice of generics or 
brand in treatment of minor illness: Those who quoted pharmacists as a source of 
information had a higher proportion of respondents who used generics in minor illness 
(p=0.021; phi coefficient=0.12). They also had a lower proportion of respondents who 
purchased based on brand (p=0.0056; phi coefficient=0.15). 
3.1.5.3 The Doctor and their influence on generic use patterns 
Overall, 43% of respondents reported that their doctor did encourage them to use generics, 
while 6% did not know. 
The following significant associations were found: 
a) Effects of the Doctor  encouraging generic medicine use on actual generic medicine 
use: (p=0.0014, Cramer’s V=0.18)  There was higher use of generics amongst those who 
reported that their doctor encouraged the use of generics, compared to those who reported 
that their doctor did not encourage generic medicine use as shown in Figure 46. 
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Figure 46: Influence of the doctor on generic medicine use 
b) Doctor’s encouragement of generic medicine use  in different Health insurance 
(medical aid) groups (p=0.0017; Cramer’s V=0.20): as shown in Figure  47, a lower 
proportion of those on a hospital plan, said that doctors had encouraged them to use 
generics, compared to those on comprehensive HI plans or those who were uninsured. The 
most encouragement for generic use was seemingly provided to comprehensively insured 
patients. This finding could allude to the influence of healthcare funders on prescribers. 
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Figure 47: Doctor’s encouragement of generic medicine use in different health insurance 
(medical aid) groups 
c) Doctor’s encouragement of generic medicine use in chronically ill respondents 
(p<0.0001; Cramer’s V=0.29): A higher proportion of those who were taking one or more 
chronic medications, said that doctors had encouraged them to use generics, compared to 
those who were not taking any chronic medications. 
d) Doctor as a source of information about generics versus doctor as a source of 
encouragement of their use (p<0.0001; Cramer’s V=0.39): A higher proportion of those 
who quoted doctors as a source of information on generics, said that doctors had 
encouraged them to use generics, compared to those who had not quoted doctors as a 
source of information on generics. 
e) Effects of Doctor’s encouragement of generic medicine use on perceptions about 
safety of generic medicines (p=0.0010; Cramer’s V=0.18): The proportion of respondents 
who reported that doctors encouraged them to use generics increased with increasing 
perception of their safety. The strength of this association was slightly weaker but 
comparable to that shown when a Pharmacist was the source of encouragement. 
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f) Effects of Doctor’s encouragement of generic medicine use on perceptions about 
quality of generic medicines (p=0.0019; Cramer’s V=0.22): The proportion of respondents 
who reported that doctors encouraged them to use generics was higher amongst those 
respondents who had very positive perceptions of the quality of generics, compared to those 
who did not. The strength of this association was similar to that shown when a Pharmacist 
was the source of encouragement. 
g) Effects of Doctor’s encouragement of generic medicine use on perceptions about 
effectiveness of generic medicines (p=0.015; Cramer’s V=0.15): The proportion of 
respondents who reported that doctors encouraged them to use generics was higher 
amongst those respondents who had positive perceptions of the effectiveness of generics, 
compared to those who did not. The strength of this association was similar to that shown 
when a Pharmacist was the source of encouragement. 
h) Effects of Doctor’s encouragement of generic medicine use on perceptions about 
side effects of generic medicines (p=0.032; Cramer’s V=0.17): The proportion of 
respondents who reported that doctors encouraged them to use generics was higher 
amongst those respondents who thought generics had same / similar / less side effects, 
compared to those who did not. The strength of this association was slightly weaker but 
comparable to that shown when a Pharmacist was the source of encouragement. 
3.1.5.4 Belief in the drug cost saving ability of generic medicines and its influence on 
generic use patterns 
Overall, 87% of respondents thought that generic medicines could help save on drug costs. 
The following significant associations were found: 
a) Effects of belief in the drug cost saving ability of generic medicines on actual use of 
generic medicines: (p<0.0001, Cramer’s V=0.24). There was higher use of generics 
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amongst those who thought that using generics can save on drug costs compared to those 
that did not think so as shown in Figure 48. 
 
Figure 48: Belief in the drug cost saving ability of generic medicines and actual generic 
medicine use 
b) Effects of belief in the drug cost saving ability of generic medicines on perceptions 
about their safety (p<0.0001; Cramer’s V=0.27): The proportion of respondents who 
agreed with the statement increased with increasing perception of the safety of generics. 
c) Effects of belief in the drug cost saving ability of generic medicines on perceptions 
about their quality (p<0.0001; Cramer’s V=0.30): The proportion of respondents who 
agreed with the statement was higher amongst those respondents who had positive 
perceptions of the quality of generics, compared to those who did not. 
d) Effects of belief in the drug cost saving ability of generic medicines on perceptions 
about their effectiveness (p=0.0003; Cramer’s V=0.21): The proportion of respondents 
who agreed with the statement was higher amongst those respondents who had positive 
perceptions of the effectiveness of generics, compared to those who did not. 
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e) Effects of belief in the drug cost saving ability of generic medicines on perceptions 
about their side effects (p<0.0001; Cramer’s V=0.34): The proportion of respondents who 
agreed with the statement was higher amongst those respondents who thought generics 
had same / similar / less side effects, compared to those who did not. 
3.1.5.5 Consideration of manufacturer when purchasing medication and its influence on 
generic use patterns 
The following significant associations were found: 
a) Effects of consideration of manufacturer on actual generic medicine use: (p<0.0001, 
phi coefficient=0.23). There was higher use of generics amongst those who did NOT 
consider the manufacturer when buying medication, compared to those who considered the 
manufacturer as shown in Figure 49. 
        
Figure 49: Effects of consideration of manufacturer on actual generic medicine use 
63.3 
83.4 
35.6 
14.3 
0
10
20
30
40
50
60
70
80
90
Yes No
%
 o
f 
re
sp
o
n
d
e
n
ts
 in
 e
ac
h
 g
ro
u
p
  
Consider manufacturer when buying medication 
Use generics: Yes No
109 
 
b) Consideration of the manufacturer in various health insurance (medical aid) groups 
(p=0.0005; Cramer’s V=0.21): A lower proportion of those not insured, said that they 
considered who manufacturers, compared to those who were insured. 
c) Consideration of manufacturer when the doctor is the source of information 
regarding generics (p=0.013; Cramer’s V=0.12): A higher proportion of those who quoted 
doctors as a source of information, said they considered manufacturers, compared to those 
who had not quoted doctors as a source of information. 
d) Consideration of manufacturer when the internet is the source of information 
regarding generics (p=0.0023; Cramer’s V=0.15): A higher proportion of those who quoted 
internet as a source of information on generics, said they considered manufacturers, 
compared to those who had not quoted internet as a source of information on generics. 
e) Effects of the consideration of manufacturer on the perceptions on safety of generics 
(p=0.044; Cramer’s V=0.15): The proportion of respondents who considered manufacturers 
was lower for those with positive perceptions of the safety of generics. 
3.1.5.6 Preferential manufacturer trust and its influence on generic use patterns 
The following significant associations were found: 
a) Effects of preferential manufacturer trust on actual generic medicine use: (p<0.0001, 
phi coefficient=0.25). There was higher use of generics amongst those who reported they 
did NOT trust some manufacturers more than others as shown in Figure 50. 
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Figure 50: Effects of preferential manufacturer trust on actual generic medicine use 
b) Preferential manufacturer trust in different health insurance (medical aid) groups 
(p<0.0001; Cramer’s V=0.25): A lower proportion of those not insured, said that they trusted 
certain manufacturers more than others, compared to those who were insured. Those on 
some kind of health insurance tended to trust certain manufacturers more. 
c) Preferential manufacturer trust where the pharmacist was the source of information 
on generics (p=0.0062; Cramer’s V=0.14): A lower proportion of those who quoted 
pharmacists as a source of information on generics, said they trusted certain manufacturers 
more than others, compared to those who had not quoted pharmacists as a source of 
information on generics. 
d) Preferential manufacturer trust  where the Doctor was the source of information on 
generics (p=0.0084; Cramer’s V=0.13): A higher proportion of those who quoted doctors as 
a source of information on generics, said they trusted certain manufacturers more than 
others, compared to those who had not quoted doctors as a source of information on 
generics. This is a reversal of the effects noted when the pharmacist was the information 
source. 
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e) Effects of preferential manufacturer trust on the perceptions about safety of generics 
(p=0.0003; Cramer’s V=0.23): The proportion of respondents who said they trusted certain 
manufacturers more than others was higher for those who felt generics were only 
moderately safe or not safe as shown in Figure 51. 
      
Figure 51: Effects of preferential manufacturer trust on the perceptions on safety of generics 
f) Effects of preferential manufacturer trust on the  perceptions about side effects of 
generic medicines (p=0.027; Cramer’s V=0.17): As shown in Figure 52, overall the highest 
of proportion of respondents who did NOT trust certain manufacturers over others felt that 
the side effects of generics were either similar or the same to those of brands. The 
proportion of respondents who said they trusted certain manufacturers more than others 
was higher for those who felt generics had fewer side effects than branded medications. 
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Figure 52: Effects of preferential manufacturer trust on the perceptions on side effects of 
generics 
3.1.6 Analysis of Knowledge vs. Perceptions  
To assess the relationships that exist between knowledge and perceptions, the questions on 
knowledge were cross-tabulated with the questions on perceptions and the results are given 
below. 
3.1.6.1 Defining a generic medicine and its effects on perceptions 
The following significant associations were found: 
a) Defining a generic medicine as a cheaper medicine and its effects on the perceptions 
about effectiveness of generic medicines: As shown in Figure 53, amongst those who 
reported a generic was a cheaper medicine, the proportion who perceived generics to be 
less effective was higher (p=0.0085; Cramer’s V=0.16). 
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Figure 53: Effects of defining a generic medicine as a cheaper medicine 
b) Defining a generic medicine as a similar medicine to the original and its effects on 
perceptions – There were no significant associations 
c) Defining a generic medicine as one with the same active as the original with a 
different name and its effects on the perceptions about quality of generics: As shown 
in Figure 54, amongst those who selected this definition of a generic medicine, the 
proportion who perceived generics to be of the same quality as other medicines was higher 
(p=0.0006; Cramer’s V=0.23. 
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Figure 54: Effects of defining a generic medicine as one with the same active as the original 
with a different name on the perceptions about quality of generics 
d) Defining a generic medicine as one with the same active as the original with a 
different name and its effects on the perceptions about effectiveness of generics: 
Amongst those who selected this definition of a generic medicine, the proportion who 
perceived generics to be as effective as other medicines was higher (p=0.0026; Cramer’s 
V=0.18). 
3.1.6.2 Sources of information about generics and their effects on perceptions 
The following significant associations were found: 
a) Effects of the Pharmacist as a source of information on perceptions about safety of 
generics: Amongst those who quoted pharmacists as a source of information, the 
proportion who perceived generics to be “safe” was higher (p=0.0012; Cramer’s V=0.20). 
b) Effects of the Doctor as a source of information on perceptions - No significant 
associations were found. 
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c) Effects of Internet as a source of information on generics on perceptions about 
quality of brand medicines: as shown in Figure 55, amongst those who quoted internet as 
a source of information, the proportion who perceived brand medicines to be of “good 
quality” rather than “very good quality” was higher (p=0.0091; Cramer’s V=0.18). 
      
Figure 55: Effects of internet as a source of information on the perceptions about quality of 
generics 
3.1.6.3 Belief in the drug cost saving effects of generics and its impact on perceptions 
The following significant associations were found: 
a) Amongst those who thought that using generics could save on drug costs, the proportion 
who perceived generics to be safe / very safe was higher (p<0.0001; Cramer’s V=0.27). The 
proportion who perceived branded medicines to be “very safe” was lower in this group 
(p=0.044; Cramer’s V=0.13). 
b) Amongst those who thought that using generics could save on drug costs, the proportion 
who perceived generics to be of good quality was higher (p<0.0001; Cramer’s V=0.30). The 
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proportion who perceived generics to be as effective as other medicines was also higher 
(p=0.0003; Cramer’s V=0.21). 
c) Amongst those who thought that using generics could save on drug costs, the proportion 
who perceived generics to have the same / similar side effects as other medicines was 
higher (p<0.0001; Cramer’s V=0.34). 
3.1.7 Analysis of Knowledge vs. Attitudes  
To assess the relationships that exist between knowledge and attitudes, the questions on 
knowledge were cross-tabulated with the questions on attitudes and the results are given below. 
3.1.7.1 Defining a generic medicine and its effects on attitudes 
The following significant associations were found: 
a) Amongst those who reported a generic was a cheaper medicine, the proportion who would 
buy the branded medicine for a major illness was higher (p=0.0054; phi coefficient=0.14). 
b) Amongst those who reported a generic was a similar medicine, the proportion who would 
buy the generic medicine for a minor illness was higher (p=0.048; phi coefficient=0.10). The 
proportion who would buy the branded medicine for a minor illness was lower (p=0.032; phi 
coefficient=0.11). The proportion who would buy the generic medicine for a major illness 
was higher (p=0.042; phi coefficient=0.11). The proportion who would buy the generic 
medicine for a chronic illness was also higher (p=0.027; phi coefficient=0.12). 
c) Amongst those who reported a generic was the same active medicine as the original, with a 
different name, the proportion who said they used generics was higher (p=0.0054; phi 
coefficient=0.14). The proportion who would buy the generic medicine for a minor illness 
was higher (p=0.0012; phi coefficient=0.17). The proportion who would buy the prescription 
medicine for a minor illness was lower (p=0.0019; phi coefficient=0.15). The proportion who 
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would buy the branded medicine for a major illness was also lower (p=0.015; phi 
coefficient=0.12). The proportion who would buy based on the pharmacist’s advice for a 
major illness was higher (p=0.036; phi coefficient=0.11). 
3.1.7.2 Sources of information about generics and their effect on attitudes 
The following significant associations were found: 
Amongst those who reported their source of information about generics was the pharmacist: 
 The proportion who said they trusted certain manufacturers more was lower (p=0.010; 
phi coefficient=0.14).  
 The proportion who would buy the generic medicine for a minor illness was higher 
(p=0.025; phi coefficient=0.12).  
 The proportion who would buy the branded medicine for a minor illness was lower 
(p=0.0056; phi coefficient=0.15).  
 The proportion who would buy the cheaper medicine for a minor illness was higher 
(p=0.025; phi coefficient=0.12). 
 The proportion who would buy the prescription medicine for a major illness was lower 
(p=0.0071; phi coefficient=0.14). 
 The proportion who would buy either a generic, branded, or cheaper medicine based on 
the pharmacist’s advice for a major illness was higher (p=0.0047; phi coefficient=0.14). 
 The proportion who would buy the branded medicine for a chronic illness was lower 
(p=0.019; phi coefficient=0.12). 
 The proportion who would buy either a generic, branded, or cheaper medicine based on 
the pharmacist’s advice for a chronic illness was higher (p<0.0001; phi coefficient=0.18). 
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Amongst those who reported their source of information about generics was the doctor: 
 The proportion who said they considered the manufacturer was higher (p=0.014; phi 
coefficient=0.12). 
 The proportion who said they trusted certain manufacturers more was higher 
(p=0.011; phi coefficient=0.13). 
 The proportion who would buy the prescription medicine for a major illness was 
higher (p=0.0071; phi coefficient=0.14). 
 The proportion who would buy either a generic, branded, or cheaper medicine based 
on the pharmacist’s advice for a chronic illness was lower (p=0.0042; phi 
coefficient=0.14). 
Amongst those who reported their source of information about generics was the internet: 
 The proportion who said they considered the manufacturer was higher (p=0.0039; 
phi coefficient=0.15).  
 The proportion who would buy based on the pharmacist’s advice for a chronic illness 
was lower (p=0.0070; phi coefficient=0.13). 
3.1.7.3 Belief in the drug cost saving ability of generics and its effect on attitudes 
The following significant associations were found: 
Amongst those who thought using generic medicines could save on drug costs,  
 The proportion who said they used generics was higher (p<0.0001; phi coefficient=0.24). 
 The proportion who would buy the branded medicine for a minor illness was lower 
(p<0.0001; phi coefficient=0.25). 
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 The proportion who would buy the branded medicine for a major illness was lower 
(p=0.015; phi coefficient=0.14). 
 The proportion who would buy the prescription medicine for a chronic illness was higher 
(p=0.046; phi coefficient=0.11).   
3.1.8 Analysis of Perceptions vs. Attitudes  
To assess the relationships that exist between perceptions and attitudes, the questions on 
perceptions were cross-tabulated with the questions on attitudes and the results are given 
below. 
The following significant associations were found: 
3.1.8.1  Perceptions on safety of generic and branded medicines and their effect on 
attitudes 
Amongst those who perceived generic medicines to be safe / very safe, 
 The proportion who said they used generics was higher compared to those with 
negative perceptions of the safety of generics (p<0.0001; Cramer’s V=0.41).  
 The proportion who said they considered the manufacturer was lower compared to 
those with negative perceptions of the safety of generics (p=0.044; Cramer’s V=0.15). 
 The proportion who said they trusted some manufacturers more than others was lower 
compared to those with negative perceptions of the safety of generics (p=0.0003; 
Cramer’s V=0.22). 
 The proportion who said they would buy the generic for minor illnesses was higher 
compared to those with negative perceptions of the safety of generics (p<0.0001; 
Cramer’s V=0.25). 
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 The proportion who said they would buy the branded medicine for minor illnesses was 
lower compared to those with negative perceptions of the safety of generics (p<0.0001; 
Cramer’s V=0.35). 
 The proportion who said they would buy the branded medicine for chronic illnesses was 
lower compared to those with safe/negative perceptions of the safety of generics 
(p=0.014; Cramer’s V=0.17). 
Amongst those who perceived branded medicines to be “very safe”,  
 The proportion who said they would buy the prescription medicine for major illnesses 
was lower compared to those with safe/negative perceptions of the safety of branded 
medicines (p=0.0017; Cramer’s V=0.18). 
3.1.8.2 Perceptions on quality of branded and generic medicines and their effect on   
attitudes 
Amongst those who perceived the quality of branded medicines to be the same as that of other 
medicines,  
 The proportion who said they used generics was higher. (p=0.042; Cramer’s V=0.16). 
 The proportion who said they would buy the branded medicine for minor illnesses was 
lower (p=0.041; Cramer’s V=0.16). 
Amongst those who perceived the quality of branded medicines to be good or the same as that 
of other medicines,  
 The proportion who said they would buy the branded medicine for major illnesses was 
lower (p=0.032; Cramer’s V=0.16). 
Amongst those who perceived the quality of generic medicines positively,  
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 The proportion who said they used generics was higher (p<0.0001; Cramer’s V=0.35).   
Amongst those who perceived the quality of generic medicines as good or the same as that of 
other medicines,  
 The proportion who said they would buy the generic medicine for minor illnesses was 
higher (p=0.0007; Cramer’s V=0.22).  
 The proportion who said they would buy the branded medicine for minor illnesses was 
lower (p<0.0001; Cramer’s V=0.40). 
Amongst those who perceived the quality of generic medicines to be of low quality,  
 The proportion who said they would buy the branded medicine for major illnesses was 
higher (p=0.032; Cramer’s V=0.16). 
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3.1.8.3 Perceptions on effectiveness of generic medicines and their effects on attitudes 
Amongst those who perceived the effectiveness of generic medicines positively,  
 The proportion who said they used generics was higher (p<0.0001; Cramer’s V=0.46).   
Amongst those who perceived the effectiveness of generic medicines as the same as that of 
other medicines,  
 The proportion who said they would buy the generic medicine for minor illnesses was 
higher (p<0.0001; Cramer’s V=0.28).  
 The proportion who said they would buy the branded medicine for minor illnesses was 
lower (p<0.0001; Cramer’s V=0.41). 
3.1.8.4 Perception of side effects of generic medicines 
Amongst those who perceived the side effects of generic medicines as the same / similar to 
other medicines,  
 The proportion who said they used generics was higher (p<0.0001; Cramer’s V=0.41).   
Amongst those who perceived generic medicines to have less side effects,  
 The proportion who said they trusted some manufacturers more than others was higher 
(p=0.027; Cramer’s V=0.17). 
Amongst those who perceived the side effects of generic medicines positively, 
 The proportion who said they would buy the generic medicine for minor illnesses was 
higher (p=0.033; Cramer’s V=0.17). 
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Amongst those who perceived the side effects of generic medicines to be the same / similar as 
that of other medicines,  
 The proportion who said they would buy the branded medicine for minor illnesses was 
lower (p<0.0001; Cramer’s V=0.32). 
Amongst those who perceived the side effects of generic medicines to be the same as that of 
other medicines,  
 The proportion who said they would buy the branded medicine for major illnesses was 
lower (p=0.0015; Cramer’s V=0.22). 
Amongst those who perceived the side effects of generic medicines to be the same/similar as 
that of other medicines,  
 The proportion who said they would buy the branded medicine for chronic illnesses was 
lower (p=0.040; Cramer’s V=0.16). 
Amongst those who perceived the side effects of generic medicines to be the same/less as that 
of other medicines,  
 The proportion who said they would buy based on the pharmacist’s advice for chronic 
illnesses was lower (p=0.017; Cramer’s V=0.18). 
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CHAPTER 4 - DISCUSSION 
4.1 Introduction 
The main objective of this chapter is to outline and explain the results presented in chapter 3 
above. The format of the discussion is laid out to follow the flow in which the results were 
presented. This chapter will in addition contain an evaluation of the methodologies used in this 
research as well as provide suggestions for further research. 
4.2 Demographics  
A total of 402 respondents participated in the study which showed a very good response rate. 
The sample was slightly favoured towards females (57%; p=0.0012). This is consistent with the 
country’s gender demographics. This is also consistent with the finding that the major clientele 
in pharmacies are female (Kjoenniksen, Lindbaek, & Granas, 2006) and females consume 
comparatively more medicines than males (Astrand, Hovstadius, Antonov, & Petersson, 2007). 
Furthermore females are generally more likely to participate in surveys (Tolonen, Helakorpi, 
Talala, Helasoja, Martelin, & Prattala, 2006).  
There was a large representation of the black (47.8%) and white (39.1%) racial groups in this 
sample. As selection to participate in the study was random this perceived bias most likely 
alludes to the racial demographics of the Johannesburg north region. Ideally comparisons 
between racial groups were to be limited to the main groups that are stated above. However, 
comparisons included the Indian (8.2%) and Coloured (4.2%) groups as these demographic 
groups are essential in explaining various aspects of the research aims and objectives within 
the context of the South African population. The Asian (0.5%) group was too low for inclusion 
into any analysis. The reason for a low Asian representation may have been due to low levels of 
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this demographic group in the study area as well as language barriers. Further research can be 
conducted with a greater representation of the Indian, Coloured and Asian groups.   
The main age group was the 30-39 year olds (31.8%) followed by the 18-29 year olds (26.4%). 
The elderly (50+ year olds) (18.9%) were the least represented. The education and English 
language skill levels were high with a large portion of the sample (43.5%) having completed 
tertiary education. As expected for this sample, household income levels were overall high 
(Statistics South Africa, 2012) with a significant portion of the sample earning more than 
R25 000 rand per month (32.8%, P<0.05). Also, as expected from the high household income 
levels, the majority of the sample (60.7%) had comprehensive health insurance (medical aid).  
The majority also visited a pharmacy at least once a month (61%) and a significant portion 
visited a pharmacy several times a month (13.7%). A large portion of the sample was on at least 
one prescription medicine (38.3%) and a large portion was on at least one chronic medicine 
(24.2%) at the time of the study. This shows high levels of medication use in this population. 
Coupled with the high levels of health insurance, this supports the view that those high income 
earners who typically live in areas such as the study area (northern suburbs of Johannesburg) 
contribute significantly to healthcare expenditure in the country (National Treasure: 
Intergovernmental Fiscal Review, 2010). 
4.3 Knowledge about generics 
By definition, a generic medicine contains the same active as the original, has a different name 
from the original, and is often cheaper than the original (WHO, 2013). These are 3 key elements 
that can be used to define generics. Only 5% of the respondents were able to bring together all 
3 elements in their selection of responses that define a generic. This reveals that an alarming 
majority of the sample did not really know what a generic was. This result is in line with a study 
conducted in Malaysia, where most of the Malaysian consumers did not know what generic 
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medicines were (Thomas & Vitry, 2009). A pivotal study in Auckland, New Zealand also showed 
that about half of the survey participants’ were not familiar with the term ‘‘generic medicine” 
(Babar et al., 2010). In comparison a study conducted in Brazil showed that 70% of the 
consumers knew that generic medicines were both cheaper and equivalent to the brand-name 
medicines (Bertoldi, Barros and Hallal, 2005).  
The results of the respondent definitions of a generic largely showed a disconnected and 
incomplete understanding of the term “generic medicine”. The highest definition choice was the 
sole selection of a generic medicine as a cheaper medicine (43.6%). This was followed by those 
who were able to bring two of the key defining elements together by selecting that a generic 
medicine has the same active ingredient as the original and has a different name (34.4%). The 
next large grouping was those who defined a generic as a similar medicine to the original 
(30.3%) which is an ambiguous response choice as similarity could mean different active 
ingredients with the same indication, for example, and this scenario does not constitute the 
definition of a generic medicine. None of the respondents thought that a generic medicine was a 
better medicine than the original. 
These results are consistent with other studies such as the results of the Sharrad and Hassali 
study which indicated that some people do not know the term ‘‘generic medicines’’ as such but 
possibly are aware of or have had experience with a cheaper or commercial, equivalent 
alternative to a brand-name medicine (Bertoldi, Barros, & Hallal, 2005). 
Defining a generic medicine as the same active with a different name had significant 
associations with certain demographic variables. This definition was used more as education 
level (p=0.015; Cramer’s V=0.15) and English language skill (p=0.0060; Cramer’s V=0.16) 
increased as well as with increasing household income (p=0.014; Cramer’s V=0.16) and 
number of medications taken. This result is consistent with the Quintal and Mendes study in 
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Portugal which also showed differences in knowledge about generics across groups. Their 
results suggested the existence of a positive association between knowledge, on one hand, and 
higher level of education, experience with medication and discussion with a doctor, on the other 
(Quintal & Mendes, 2011).  
This result was also similar to the Auckland study where participants from the North Shore 
(where the majority of the residents are affluent) were more aware of generic medicines. They 
perceived generic medicines to have an equivalent quality and efficacy to brand medicines and 
to be more affordable and safe. These participants were also more willing to accept generic 
medicines (Babar et al., 2010). 
Pharmacists were the highest source of information on generics (70.8%) and together with 
Doctors (39.0%) were the main sources of information on generics followed by the internet 
(16.9%). Other sources had negligible rates of use. This is consistent with the Auckland study 
which showed that pharmacists were most likely to inform consumers; this could be since they 
have more knowledge on medications and are in frequent contact with patients. Doctors were 
second in line to inform consumers (Babar et al., 2010). Other studies also indicate that 
pharmacists are a more common source of information on generics (Kjoenniksen, Lindbaek, 
and Granas, 2006) or that pharmacists and physicians are both likely sources of information for 
patients (Gaither, Kirking, Ascione, and Welage, 2001).  
Of interest in this study, doctors provided information about generics more to the 
comprehensively insured respondents (average 49.4%) compared to uninsured respondents 
(27.7%) or respondents on hospital plans (31.6%) (see Table 7). This may allude to the 
influence of healthcare funders on the prescriber as they target the prescribers to promote 
generic medicine use amongst their members in order to save on drug costs. The internet was 
more highly used as a source of information amongst the White (25.6%) and Indian (18.2%) 
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groups as well as the more educated, higher earning, insured, and the more regular pharmacy 
visiting respondents (see Table 7). 
The majority of respondents thought that using generics could save on drug costs (86%). 
However, the level of agreement was strangely lower amongst the uninsured group (p<0.0001; 
Cramer’s V=0.19) who probably need to be in agreement more. This shows a gap in knowledge 
in this group. 
4.4 Attitudes 
The majority of respondents (78%) indicated that they actually used generics. However the level 
of use was lower amongst the highest education category (p<0.0001; Cramer’s V=0.18) even 
though this group tended to be knowledgeable about generics. Most respondents did not 
consider manufacturer when purchasing medication (76.2%) neither did they trust certain 
manufacturers over others (77.2%). However Whites and Indians had a higher level of 
consideration of manufacturers than Blacks and Coloureds (p=0.0028; Cramer’s V=0.16). The 
more educated (p<0.0001; Cramer’s V=0.19), higher income earning respondents (p=0.041; 
Cramer’s V=0.13) also tended to consider manufacturers and those who were not insured had 
less consideration of manufacturers (p=0.0027; Cramer’s V=0.16). The same trends were found 
when the respondents were asked if they trusted certain manufacturers over others. 
Generics were the overall favourite for use in minor illness (41%). However trends changed as 
brands were more popular than generics in major illness (10% opted for generics in this 
scenario). The trend continued even amongst the lower income groups and the uninsured. This 
is similar with a finding in the US Tenncare study which showed that patients who constituted 
the lower income group were strangely not receptive to taking generic medication themselves 
(Keenum et al., 2012).  
129 
 
For major (30.7%) and chronic illness (54.7%), respondents mostly preferred to go with the 
exact prescribed medication. This is consistent the results of the study carried by Chong et al. 
which revealed that in Australia, chronic patients had significantly lower levels of acceptance of 
generic substitution than acute patients. Furthermore, chronic patients who were stabilized on a 
brand product may have been reluctant to switch their therapy in case the alternative brand was 
not as effective (Chong et al., 2011). A study from Finland found similar findings where patients 
tended to refuse substitution if they had positive experiences with medicines they had used 
previously (Mott & Kline, 2002). 
The use of generics generally decreased with increasing severity of illness (40.7% in minor 
illness to 9.7% and 5.1% in major and chronic illness respectively) (Figure 23). This reveals an 
underlying attitude problem within the respondents in this sample. Whites and Coloureds tended 
to select generics more than Blacks and Indians (p=0.016; Cramer’s V=0.16) in minor illness 
and the top two household income brackets also favoured generics the most in minor illness. 
Generic use in major illness was significantly higher amongst those on Hospital plans (p=0.029; 
Cramer’s V=0.15) and generic use in chronic illness was significantly higher amongst the Indian 
group (p=0.0053; Cramer’s V=0.18) as well as amongst those who visited the pharmacy more 
frequently (p=0.0022; Cramer’s V=0.18). Those taking more chronic medications also 
increasingly tended to select generics (p=0.0065; Cramer’s V=0.14) possibly due to experience 
with medication use as well the need to cut on medication costs. 
The Auckland study showed similar results where more than three quarters of the participants 
were willing to use a generic medicine for a minor illness but there were fewer people who were 
willing to change to a generic medicine for a major illness (Babar et al., 2010). Other studies 
have also indicated that consumers are less likely to use generics for chronic or serious 
conditions (Kjoenniksen et al., 2006; Ganther & Kreling, 2000; Hassali et al., 2005). 
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It is also evident from the results that the respondents tended to put their trust more in the 
prescriber as illness severity increased. This result is similar to the findings of Patel et al. 
conducted in South Africa where respondents tended to trust the advice received from private 
prescribing doctors more than that of other providers such as pharmacists. Participants in that 
study also tended to be influenced more by their doctor, rather than the pharmacist, when 
deciding whether or not to use generic prescription medicines (Patel, Gauld, Norris, and Rades, 
2010). 
4.5 Perceptions 
Perceptions on the safety of generics were predominantly positive (80% responded generics 
were safe to very safe). However perceptions on the safety of brands were significantly more 
positive relative to generics (95%). Those who had very positive perceptions on the safety of 
brands tended to have significantly more negative perceptions on the safety of generics 
(p<0.0001). The overall finding on perceptions in the study was contradictory to the Auckland 
study where the result was predominantly negative with less than half of participants in the 
study perceiving generic medicines to be as safe, effective and equivalent in quality or less 
costly than brand medication. Also less than half of the respondents perceived generics to be 
tested as rigorously as brand medicines (Babar et al., 2010). 
 Indians and Coloureds showed a higher level of positive perception on generic safety 
compared to Whites and Blacks (p=0.0005; Cramer’s V=0.16). As level of education increased, 
the level of positive perception on safety of generics also increased (p=0.0084; Cramer’s 
V=0.15). The comprehensively insured also had a more positive perception of safety than the 
uninsured and those on hospital plans (p=0.022; Cramer’s V=0.13). 
Though perceptions on the quality of generics were generally positive (64%), in contrast the 
perceptions on the quality of brands were significantly and predominantly more positive (93%). 
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Those who had a very positive perception on the quality of brands tended to have a significantly 
more negative perception on the quality of generics (p<0.0001). As household income 
increased, the perception of the equivalence of quality of generics and brands increased 
(p=0.0006; Cramer’s V=0.17).  
Blacks (53.8%) and Indians (60.6%) had the most positive perceptions on the quality of brands 
(Figure 33). Indians also had the most positive perceptions on the quality of generics whilst the 
other races had comparable levels of perception in this regard (Figure 34). Coloureds tended to 
use the term “very good quality” the most when expressing their perceptions on the quality of 
generics. Those on comprehensive health insurance had the highest positive perceptions on the 
quality of generics (p=0.0029; Cramer’s V=0.16). Those taking more medications also had a 
higher positive perception of the quality of generics (p=0.016; Cramer’s V=0.18).  
The majority of respondents in this study felt that the effectiveness of generic medicines was the 
same as that of brands (75%). However there was a significant portion of respondents who felt 
that generics were less effective than brands (17.4%). There was a significant difference 
between the proportion of respondents who indicated generic medicines were ‘less effective’ 
and those who indicated ‘as effective’ (p<0.0001). The majority of respondents felt that the side 
effects of generics were similar (42%) to or the same (20%) as those of brands. This perception 
tended to increase with increasing level of education (p<0.0001; Cramer’s V=0.22), as well as 
increasing medicine use (p=0.0037; Cramer’s V=0.21). However a significant proportion of 
respondents felt that brands had fewer side effects than generics (14.6%; p<0.05). 
These results are similar to findings in New Zealand where it was revealed that though generics 
are commonly used, the public may simply associate generics with inferior products (Minutes of 
the PHARMAC Consumer Advisory Committee, 2007). Several literature references are also 
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available that also suggest that consumers believe that generics are sub-standard and have 
quality issues (King & Kanavos, 2002; Generic Medicines, 2007; Medsafe, 2012). 
The results on the perception about quality may indicate an underlying misconception on what 
the quality of a medicine means. As explained to the respondents during the survey, WHO 
defines quality of a medicine in terms of its suitability to meet its intended use as determined by 
its efficacy when weighed against its safety, label/claim, how it’s promoted or publicized, and its 
conformity to specifications regarding purity, identity and other characteristics.  
In a study carried out by Patel et al. in Durban, Johannesburg and Cape Town from 2006-2008, 
for consumers, the main descriptor of quality was the effect of the medicine on their symptoms. 
Terms used to describe quality included “drug works” and “strong medicine”. Concerns about 
the actual quality of medicines were also explicitly raised by the public sector pharmacists that 
were interviewed in the study. Procurement and use behaviour of generics by healthcare 
providers was influenced by prior experience, manufacturers’ names and consumers’ ability to 
pay. However actual analysis of samples of generics and brands conducted during the study 
showed equivalence of the two as all samples passed in vitro tests for quality (Patel, Gauld, 
Norris, and Rades, 2012). 
4.6 Influences on patterns of generic medicine use 
Actual generic medicine use was positively influenced by: 
 A positive perception of their safety (p<0.0001; Cramer’s V=0.41), quality (p<0.0001; 
Cramer’s V=0.35), effectiveness (p<0.0001; Cramer’s V=0.46), and equivalence of side 
effects with other medicines (p<0.0001; Cramer’s V=0.41). 
 Pharmacist (p<0.0001, Cramer’s V=0.25) and Doctor (p=0.0014, Cramer’s V=0.18) 
encouragement. This is consistent with the Mott and Cline study which showed that both 
133 
 
prescribers and pharmacists play a significant role in whether patients receive generic 
medication (Mott & Cline, 2002) 
 Belief in the drug cost saving ability of generics (p<0.0001, Cramer’s V=0.24).  
 An attitude of non-consideration of the manufacturer of the product when purchasing 
(p<0.0001, phi coefficient=0.23). 
 An attitude of non-preferential trust of the manufacturer of the product (p<0.0001, phi 
coefficient=0.25). 
 Experience with medication use. This result is consistent with the Iraq study which 
showed that consumers with experience of generic medicines generally had a more 
positive perception of them in the Iraq study (Sharrad & Hassali, 2011). Similar results 
were found in a survey on consumers’ perceptions of generic substitution conducted 
amongst a sample of 505 consumers in the United States (Sansgiry & Bhosle, 2004) and 
in a study conducted amongst a sample of 804 patients in Germany (Himmel, 
Simmenroth-Nayda, Niebling et al., 2005).   
Overall, these results were contradictory to the US Tenncare study where participants 
interviewed in that study were well aware of the overall benefits of generic medication (e.g., 
cost savings, equally efficacious, similar side effects). However, when it came to personal 
preference, a much smaller proportion of participants wanted to take generics over brand-
name medications (Keenum et al., 2012). 
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4.7 Knowledge versus Perceptions 
Defining a generic medicine incorrectly or incompletely was generally associated with negative 
perceptions about them (Figure 53). For example those who defined generics solely as cheaper 
medicines tended to think they were less effective (p=0.0085; Cramer’s V=0.16) whereas those 
who were able to define them as the same active ingredient with a different name had a more 
positive perception of their quality and effectiveness (p=0.0006; Cramer’s V=0.23). The notion 
that consumers may consider cheaper generics as inferior in quality or effectiveness was also 
revealed in a study carried out in Melbourne, Australia in 2005 (Hassali et al., 2005) 
Other studies, such as the Auckland study, also revealed that those participants who were not 
familiar with generic medicines had misconceptions and considered them as unsafe and not 
equivalent in terms of quality and effectiveness. In addition, these participants were not aware of 
the fact that generic medicines were less costly than brands and were tested as strictly as 
brands (Babar et al., 2010). 
When the Pharmacist was the source of information on generics there was generally a higher 
perception of their safety (p=0.0012; Cramer’s V=0.20). There were no significant associations 
with perceptions when the Doctor was the source of information.  
Belief in the drug cost saving ability of generics was generally associated with positive 
perceptions about their safety (p<0.0001; Cramer’s V=0.27), quality (p<0.0001; Cramer’s 
V=0.30) and equivalence with brands in their side effects (p=0.0003; Cramer’s V=0.21). 
4.8 Knowledge versus Attitudes 
Defining a generic medicine incorrectly or incompletely was generally associated with negative 
attitudes about them. Those who defined generics solely as cheaper medicines tended to pick 
brands more for major illness (p=0.0054; phi coefficient=0.14). Those who defined generics as 
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the same active medicine as the original with a different name, tended to use generics more 
(p=0.0054; phi coefficient=0.14). 
When the Pharmacist was the source of information regarding generics; preferential 
manufacturer trust was lower (p=0.010; phi coefficient=0.14), generic use in minor illness was 
higher (p=0.025; phi coefficient=0.12), brand use in minor illness was lower (p=0.0056; phi 
coefficient=0.15), selection of the cheaper medicine in minor illness was higher (p=0.025; phi 
coefficient=0.12), selection of the exact prescribed medication in major illness was lower 
(p=0.0071; phi coefficient=0.14), purchasing based on Pharmacists advice was higher 
(p=0.0047; phi coefficient=0.14), and brand use in chronic illness was lower (p=0.019; phi 
coefficient=0.12). This shows the importance of the Pharmacist as the expert and custodian of 
medicines in influencing generic medicine use. 
When the Doctor was the source of information regarding generics; manufacturer consideration 
(p=0.014; phi coefficient=0.12) and preferential manufacturer trust was higher (p=0.011; phi 
coefficient=0.13), purchase of the exact prescribed medicine in major illness was higher 
(p=0.0071; phi coefficient=0.14), and purchasing based on Pharmacists advice in chronic illness 
was lower (p=0.0042; phi coefficient=0.14). This result is similar to the results of a study carried 
out in Greece which showed though doctors seemed positive about generics, other factors 
came into play when actually prescribing and many of them chose original products (Tsiantou et 
al., 2009). 
 In addition, in a Finish study, in 2007, the majority of medical doctors were positive with 
generics substitution but sceptical about their quality in terms of their efficacy and safety for 
some drug categories (Heikkila et al., 2007). This result could be a revelation of an underlying 
negative attitude of Doctors to specific generic manufacturers and needs to be examined 
further.  
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When the Internet was the source of information regarding generics, consideration of 
manufacturer was higher (p=0.0039; phi coefficient=0.15) and the proportion of respondents 
who would buy a medicine based on the pharmacist’s advice for a chronic illness was lower 
(p=0.0070; phi coefficient=0.13). 
Belief in the cost saving ability of generics resulted in higher generic medicine use (p<0.0001; 
phi coefficient=0.24) and lower use of brands (p<0.0001; phi coefficient=0.25). 
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4.9 Perceptions versus Attitudes 
Generally positive perceptions on the safety, quality, effectiveness and side effects of generics 
were associated with positive attitudes towards them and greater actual use of generics. 
4.10 Evaluation of methodologies 
The data collection tool of the researcher administered questionnaire was effective in meeting 
the aims and primary objectives of the research. Question selection was well thought out and 
relevant to the topic. Many explanatory variables were also included to assist further analysis of 
the data. However, more use of open ended questions could have been employed to give 
respondents more freedom. The structure of the questionnaire could also have been improved 
for example by shifting demographic data to the end of the questionnaire so that main objectives 
of the research are covered first in the collection of data. Another example of improvements that 
could have been made includes the use of a more clear scale with the questions on perceptions 
to assist the respondents in determining the progression from positive to negative perceptions.   
Furthermore, a more thorough collection of the views of the respondents may have been 
achieved by the inclusion of a focus group discussion. Overall, the fact that the researcher 
administered the questionnaires himself aided in the explanation of the survey questions and 
the various scales employed. It also allowed the researcher to pick up on issues that are not 
possible to ascertain in any other way during the survey such consumer expressions and 
environmental issues. 
The sampling of pharmacies was well conducted and resulted in a well constituted respondent 
sample that the researcher was expecting. This mainly consisted of the higher income earning, 
health insured individuals who are the main contributors to healthcare expenditure in the 
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country. Statistical analyses were thoroughly performed and were able to elucidate the many 
complex associations that existed within the respondents as they went through the survey.  
4.11 Areas for further research 
As mentioned in other sections above, further research of the same nature can be conducted 
with a greater representation of the Indian, Coloured and Asian communities. A study with a 
greater representation of the elderly can also be conducted to gain greater insight from this 
group. Furthermore, further research in the same area could include more complex data 
collection tools such as focus group discussions that will help reveal deeper views of the 
sample.  
In this study, Healthcare professionals turned out to have a significant impact on consumers of 
healthcare . It is therefore fitting that attention also needs to be brought to health professional 
perceptions, knowledge and attitudes towards generic medicines as they ultimately impact the 
patient. Studies also need to be designed to compare the views of private sector health 
professionals to public sector health professionals. 
Research also needs to be conducted to examine additional issues such as inter-generic 
perceptions and attitudes with a more detailed comparison of generics made by different 
manufacturers. In addition, examination of the psychological aspects involved when faced with 
different generics that have different appearances, colours, shapes etc… and their impact on 
patient choices, and adherence to treatment. 
Further research also needs to be conducted to elucidate the inter-racial perceptions of brands 
to explain why Blacks and Indians seem to have a significantly higher brand association with 
quality? The question needs to be answered on whether this association is limited only to 
medicines or is it a general trend amongst Blacks and Indians regardless of what is being 
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purchased. It also needs to be clarified through sound research if the extent of brand 
prioritization is dynamic or static across a spectrum of products being purchased e.g. medicines 
versus luxuries. 
The question of “who is winning the drug wars in South Africa – Generics versus Brands?” also 
needs to be answered with a more thorough comparison of generics versus brands that 
includes multiple facets such as financial performance of innovator versus generic companies, 
market shares and growth, comparisons of consumer perception, knowledge and attitudes, 
various policies and their impact, and stakeholder holder influences to mention a few. 
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CHAPTER 5 – CONCLUSIONS 
5.1 Study conclusions 
Study Objective 1 - To gauge perceptions regarding the safety, quality and efficacy of generic 
medicines as well as compare these with brand medicines. 
Perceptions regarding safety, quality, efficacy, and side effects of generic medicines were 
generally positive but responses proved even more positive for brands. More positive 
perceptions of brands were associated with a shift towards more negative perceptions towards 
generics. 
Study Objective 2 - To assess consumer’s level of knowledge regarding generics. 
For consumers of healthcare in the Northern Suburbs of Johannesburg South Africa, the level of 
knowledge of generics was overall low, and incomplete.  
Study Objective 3 - To ascertain willingness to use generic drugs and reasons behind decision. 
Attitudes towards generic medicines were mostly positive however willingness to use generics 
lessened with increasing severity of illness.  
Pharmacists and Doctors had a positive influence on generic use patterns. However, with 
increasing severity of illness, Doctors influence was higher and there was a corresponding 
decrease in the use of generics.  
Study Objective 4 - To establish ways to influence generic use patterns in the higher income 
population of South Africa. 
Other factors also positively influenced generic use patterns such as belief in their drug cost 
saving ability, non-consideration and non-preferential manufacturer trust, experience with 
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medicines, and positive perceptions about the safety, quality, effectiveness, and side effects of 
generics. 
Study Objective 5 - To describe the demographic variables measured as well as explain them in 
terms of their effect on the other variables measured. 
Demographic variables such as household income, health insurance status, level of education, 
experience with medicine use, and racial demographics had significant influences on consumer 
beliefs and behaviours regarding medicine use. 
5.2 Study recommendations 
The knowledge gap on generics needs to be filled in this population. Clear, correct, and 
consistent campaigns need to be conducted to disseminate information regarding generics, to 
the public. The influence of key healthcare professionals such as Pharmacists and Doctors 
needs to be used in these campaigns. Initiatives by the government also need to target the 
private sector more as this sector is an essential target for cost containment. Different types of 
media such as print media and social media need to be employed in increasing amounts, to 
facilitate discourse on the subject of generics. 
Awareness regarding quality issues of medicines needs to be raised and this can be achieved 
through the aid of focus groups. 
Doctor attitudes towards generics and certain manufacturers need to be examined more closely 
and their perceptions about generics and manufacturers of these generics need to be managed. 
Scientific and evidence based approaches need to be employed in increasing amounts to 
facilitate this process.  
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5.3 Value of study outcomes 
For Managed Healthcare providers 
The outcomes of this study are valuable to organizations involved in managed healthcare such 
as Medical Aid Schemes and managed healthcare consultants. As healthcare costs have 
continued to rise there has been a greater shift towards cost cutting initiatives such as 
promotion of generic medicine use by Medical Aid Schemes. It is therefore valuable for 
managed healthcare providers to know if the main demographic group that is on private Medical 
Aid Schemes (as represented well in this study), is assimilating generic drugs to the extent that 
is required for effective cost reduction. It is also important for them to know what issues are 
negatively impacting the use of generics so that they can deal with them accordingly for 
example whether to design more strategies targeting Doctors in order to promote an increase in 
generic prescribing patterns. 
For the South African government 
From a public health perspective, the results of this study are useful to the Department of 
Health. Any negative perceptions and attitudes towards generic medicines have a deleterious 
effect on the implementation of the South African National drug policy and on the imminent 
National Health Insurance (NHI) system. Furthermore, healthcare care budgets will continue to 
spiral out of control if the major consumers of healthcare does do not cut down drastically on 
expenditures. 
For Manufacturers of Generic Medicines 
From a business perspective, the outcomes of this study are of value to generic medicine 
manufacturers. The results can be used to help them establish where they stand in the eyes of 
the major consumers of healthcare. This knowledge can be used to help them position 
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themselves better in the pharmaceutical market as well as develop specific well informed 
strategies to promote the use of generic products. 
For Manufacturers of Branded Medicines 
From a business perspective, the outcomes of this study are also of value to brand medicine 
manufacturers. The results can also be used to help them establish where they stand in the 
eyes of the major consumers of healthcare. This knowledge can be used to help them position 
themselves better in the pharmaceutical market as well as develop specific well informed 
strategies to promote the use of branded products. For example increasing strategies targeted 
towards the Black and Indian middle class communities to perpetuate the positive perceptions 
and attitudes towards branded medicines. 
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APPENDIX A 
THE QUESTIONNAIRE IS ATTACHED 
  
          Pharmacy #/ Participant #                 Initials                                 Visit Date 
KNOWLEDGE, 
PERCEPTIONS 
AND ATTITUDES 
TOWARDS 
GENERICS     
 
 Page 1 of 5         
   /          /   /    
                                                                           
                                                                                  DD                MM                YY 
 
Completed by: Date: Signature: 
 
 
DEMOGRAPHICS: 
 
 
Age: 
 
 years 
 
Gender: 
 
 Male  Female 
 
Race: 
 
 Black  White  Colored 
 
 
 
 Asian  Indian  Other _______________ 
 
HIGHEST LEVEL OF EDUCATION ATTAINED: 
 
No Schooling:  
 
Primary school, not complete:  
 
Primary school, complete:  
 
Secondary school, not complete:  
 
Secondary school complete:  
 
Attended college or university:  
 
ENGLISH LANGUAGE SKILL: 
 Poor  Good 
 Very Good  Excellent 
HOUSEHOLD INCOME IN RANDS: 
< R 10 000  R 10 000 – R 20 000 
 R 20 000 – R 25 000  > R 25 000 
   
 
HEALTH INSURANCE STATUS: 
 
 Not insured   Comprehensive cover (All medicines and Hospital cover) 
 Hospital plan only:   Only covers the formulary drugs and Hospital 
 Only covers prescription drugs and Hospital 
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Completed by: Date: Signature: 
 
 
 
WHO PAYS FOR YOUR HEALTH INSURANCE? 
 
Self:  
Employer:  
I pay part and my employer pays the other part:  
I don’t have health insurance  
NUMBER OF VISITS TO THE PHARMACY (CHOOSE BEST ANSWER) 
Once in a while:  
At least once a month:  
Several times a month:  
At least once a week:  
Several times a week:  
NUMBER OF PRESCRIPTION MEDICATIONS CURRENTLY TAKEN: 
None   
1-5  
More than 5  
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Completed by: Date: Signature: 
 
 
 
 
 
 
NUMBER OF CHRONIC MEDICATIONS CURRENTLY TAKEN (These are the medications you take every month) : 
 
None  
1-5  
More than 5  
 
WHAT IS A GENERIC MEDICINE? (Tick all that apply): 
 
 Another brand  A cheaper medicine  A similar medicine to the original 
 A better medicine than the original 
 The same active medicine  as the 
original with a different name  
 Not sure 
WHAT IS YOUR SOURCE OF INFORMATION REGARDING GENERICS? (Tick all that apply): 
 Pharmacist 
 
 Doctor 
 
 Other health professionals  
 Internet 
 
 Magazines/newspapers 
 
 Family/friends 
 Textbooks/Journals 
 
 Other                         State:_________________________________ 
 
 
ANSWER YES, NO, or DON’T KNOW TO THE FOLLOWING QUESTIONS: 
 
Do you use generic medicines?  Yes  No  Don’t know 
Does your Pharmacist encourage you to use generics?  Yes  No  Don’t know 
Does your doctor encourage you to use generics?  Yes  No  Don’t know 
Do you think using generic medicines can save on drug 
costs? 
 Yes  No  Don’t know 
When you buy medication do you consider who 
manufactured it? 
 Yes  No  Don’t know 
Are there certain manufacturers you tend to trust more than 
others? 
 Yes  No  Don’t know 
          Pharmacy #/ Participant #                 Initials                                 Visit Date 
KNOWLEDGE, 
PERCEPTIONS 
AND ATTITUDES 
TOWARDS 
GENERICS     
 
 Page 4 of 5         
   /          /   /    
                                                                           
                                                                                  DD                MM                YY 
 
Completed by: Date: Signature: 
 
 
 
 
PLEASE ANSWER THE FOLLOWING QUESTIONS WITH THE MOST APPROPRIATE ANSWER: 
 
WHAT IS YOUR PERCEPTION ON THE SAFETY OF GENERIC MEDICINES? (TICK ALL THAT YOU THINK APPLY) 
 THEY ARE VERY SAFE   THEY ARE SAFE  THEY ARE NOT SAFE 
 THEY ARE MODERATELY SAFE 
 I DON’T KNOW 
 
WHAT IS YOUR PERCEPTION ON THE SAFETY OF BRANDED/ ORIGINATOR MEDICINES ? (TICK ALL THAT YOU THINK APPLY) 
 THEY ARE VERY SAFE   THEY ARE SAFE  THEY ARE NOT SAFE 
 
 THEY ARE MODERATELY SAFE 
 
 I DON’T KNOW 
The World Health Organization defines the quality of a medicine in terms of its suitability to meet its intended use as determined by its 
efficacy when weighed against its safety, label/claim, how it’s promoted or publicized, and its conformity to specifications regarding purity, 
identity and other characteristics.(http://www.who.int/trade/glossary/story078/en/index.html) 
 
 HOW DO YOU PERCEIVE THE QUALITY OF BRANDED/ORIGINATOR MEDICINES? 
 THEY ARE OF VERY 
GOOD QUALITY 
 THEY ARE OF LOW QUALITY 
 THEIR QUALITY AND THE QUALITY OF  OTHER 
MEDICINES IS THE SAME 
 THEY ARE OF GOOD 
QUALITY 
 THEY ARE OF MODERATE 
QUALITY 
 I DON’T KNOW 
 
HOW DO YOU PERCEIVE THE QUALITY OF GENERIC MEDICINES? 
 THEY ARE OF VERY 
GOOD QUALITY 
 THEY ARE OF LOW QUALITY  THEIR QUALITY IS AS GOOD AS OTHER MEDICINES 
 THEY ARE OF GOOD 
QUALITY 
 THEY ARE OF MODERATE 
QUALITY 
 I DON’T KNOW 
 
WHAT IS YOUR PERCEPTION ON THE EFFECTIVENESS OF GENERIC MEDICINES VERSUS BRANDED/ORIGINATOR 
MEDICINES? 
 MORE EFFECTIVE  LESS EFFECTIVE  AS EFFECTIVE  I DON’T KNOW 
WHAT IS YOUR PERCEPTION ON THE SIDE EFFECTS OF GENERIC MEDICINES VERSUS BRANDED/ORIGINATOR MEDICINES? 
 THE SIDE EFFECTS ARE THE 
SAME 
 GENERICS HAVE LESS SIDE 
EFFECTS 
 BRANDS HAVE LESS SIDE EFFECTS 
 THE SIDE EFFECTS ARE SIMILAR  I DON’T KNOW 
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Completed by: Date: Signature: 
 
 
 
PLEASE ANSWER THE FOLLOWING QUESTIONS ON HYPOTHETICAL SCENARIOS BASED ON WHAT YOU NORMALLY DO IN 
THAT SCENARIO OR WHAT YOU WOULD DO.  PLEASE PAY ATTENTION TO THE UNDERLINED KEY WORDS. TICK ALL THAT 
APPLY TO YOU. 
 
IN THE CASE OF A MINOR ILLNESS (e.g. common cold, minor infection) YOU ARE PRESENTED WITH THE MEDICATION 
CHOICES AVAILABLE TO YOU CONSISTING OF BRANDED/ORIGINATOR MEDICINES AND GENERIC MEDICINES. WHICH 
ANSWER BEST DESCRIBES WHAT YOU WOULD PICK? 
 
 I’D PICK THE GENERIC  I’D PICK THE BRAND 
 I’D PICK THE CHEAPER 
ONE 
 I’D PICK EXACTLY WHAT 
IS ON MY PRESCRIPTION 
 I’D LEAVE THE DECISION TO 
MY PHARMACIST 
 
 I’D PICK WHAT MY MEDICAL AID WILL PAY 
FOR 
 
 I DON’T KNOW 
IN THE CASE OF A MAJOR ILLNESS (e.g. severe infection) YOU ARE PRESENTED WITH THE MEDICATION CHOICES 
AVAILABLE TO YOU CONSISTING OF BRANDED/ORIGINATOR MEDICINES AND GENERIC MEDICINES. WHICH ANSWER BEST 
DESCRIBES WHAT YOU WOULD PICK? 
 
 I’D PICK THE GENERIC  I’D PICK THE BRAND 
 I’D PICK THE CHEAPER 
ONE 
 I’D PICK EXACTLY WHAT 
IS ON MY PRESCRIPTION 
 I’D LEAVE THE DECISION TO 
MY PHARMACIST 
 
 I’D PICK WHAT MY MEDICAL AID WILL 
PAY FOR 
 I DON’T KNOW 
IN THE CASE OF A CHRONIC ILLNESS (e.g. asthma, high blood pressure, diabetes etc…) YOU ARE PRESENTED WITH THE 
MEDICATION CHOICES AVAILABLE TO YOU CONSISTING OF BRANDED/ORIGINATOR MEDICINES AND GENERIC MEDICINES. 
WHICH ANSWER BEST DESCRIBES WHAT YOU WOULD PICK? 
 
 I’D PICK THE GENERIC  I’D PICK THE BRAND 
 I’D PICK THE CHEAPER 
ONE 
 I’D PICK EXACTLY WHAT 
IS ON MY PRESCRIPTION 
 I’D LEAVE THE DECISION TO 
MY PHARMACIST 
 
 I’D PICK WHAT MY MEDICAL AID WILL PAY 
FOR 
 I DON’T KNOW 
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A. English Informed Consent  Participant Initials: __    
B. Version 1 (Dated Sep.2012) 
C. Principal researcher: Tinashe Zigomo 
D. Approved by Wits HREC (M110635) Participant Number: __ 
E. Supervisors: S Naidoo and D Reddy 
 
Patient Information leaflet and Informed Consent 
Study title Consumer perceptions, attitudes and knowledge towards 
generic medicines – a perspective from the Northern 
Suburbs of Johannesburg 
Principal Researcher Tinashe Zigomo  
Supervisors Ms Shirona Naidoo; Mr Dakshina Reddy 
Designation Candidate in the Master of Science in Medicine 
(Pharmaceutical Affairs) degree programme 
Institution University of the Witwatersrand 
Contact number(s) 078 398 0063 
Date and time of first informed consent discussion: 
    : 
dd mmm yyyy  Time 
 
Introduction: 
Good day. You are kindly invited, as a consumer of healthcare, to volunteer to participate in 
a research study on the topic stated above. Before agreeing to participate in this research 
study, it is important that you read and understand the following explanation of the purpose 
of the study, potential benefits and your right to withdraw from the study at any time. This 
information leaflet is to help you to decide if you would like to participate. You should fully 
understand what is involved before you agree to take part in this study.  
If you have any questions, which are not fully explained in this leaflet, do not hesitate to ask 
the researcher presenting this leaflet or call the principal researcher on the contact number 
provided above. If you decide to take part in this study, you will be kindly asked to sign this 
document demonstrating your understanding of the study. You will also be given a copy to 
keep. 
Study purpose, conduct, and duration 
 The purpose of this study is to assess consumer’s perceptions, knowledge and attitudes 
towards generic medicines within the community in which you reside.  
You have been invited to volunteer to take the questionnaire. This will only take a few 
minutes of your time (approximately 20 to 30 minutes) and a friendly co-researcher will 
assist you through the process. This study will also be performed in several other 
pharmacies in your suburban region (i.e. northern Johannesburg). Approximately 400 
participants will participate in the region all in the age group of 18 – 70 years old. You will be 
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asked to answer a series of simple response questions including some that require your 
personal details (e.g. age, sex, education, income, health insurance status etc.), as well as 
questions that relate to or may influence your perceptions, attitudes and knowledge 
regarding generic medicines. Please answer the questions as truthfully as possible. I 
encourage you to feel free to ask any questions you may have about the research at any 
point. Your name will not appear on the questionnaire.  All data collected via the 
questionnaire will remain confidential and anonymous.  
Benefits 
You will not be remunerated for participation in this study. The potential benefit from your 
participation in this study may be your increased awareness on the subject of generic 
medicines. However, you may not benefit from this study. Your participation will contribute to 
the body of knowledge in this area and may help health professionals, managed health care 
providers and other people like yourself to ultimately improve on handling healthcare choices 
so as to improve the overall wellbeing of our society. 
Rights 
Your participation in this study is entirely voluntary and you have the right to decline to 
participate, or stop at any time without stating any reason. You will not suffer any 
consequences from withdrawal. 
Confidentiality 
All information obtained during the course of this study including personal data and research 
data will be kept strictly confidential. Data that may be incorporated in the write up of the 
research report or that may be reported scientifically will not include any information that 
identifies you as a participant in this study. Information will be reviewed by authorised 
representatives of the Principal researcher and his team. If a sponsor is found for this study, 
authorised representatives from the sponsor will also gain access to review of information. 
Research Information may also be inspected by the University of the Witwatersrand, and the 
University of the Witwatersrand Human Research Ethics Committee (HREC). These records 
will be utilised by them only in connection with carrying out their obligations relating to this 
study. 
Ethics 
This study has been submitted to the University of the Witwatersrand, Human Research 
Ethics Committee (HREC) and written approval has been granted by that committee. 
Informed Consent 
I hereby confirm that I have been informed by the researcher about the nature, conduct, and 
benefits of the study on ‘Consumer perceptions, attitudes and knowledge towards generic 
medicines – a perspective from the Northern suburbs of Johannesburg’. I have also 
received, read and understood the above written information (Participant information leaflet 
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and Informed consent) regarding the study. I am aware that results of the study, including 
personal details regarding my sex, age, date of birth, and initials will be anonymously 
processed into a study report. In view of the requirements of research, I agree that the data 
collected during this study can be processed in a computerised system by the Principal 
researcher and the team he has appointed. 
I may at any stage, without prejudice, withdraw my consent and participation in the study. 
I’ve had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study.  
 
 
Participant: 
 
Printed Name                                         Signature                                  Date and Time          
I herewith confirm that the above participant has been fully informed about the nature, 
and conduct of the above study. 
Researcher:     
  
Printed Name                                         Signature                                  Date and Time                            
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